NANOPARTICLES HAVING OLIGONUCLEOTIDES
ATTACHED THERETO AND USES THEREFOR

This application is a continuation-in-part of pending

PCT application PCT/US97/12783, which was filed July 21,

10   1997, and which claimed benefit of provisional application

number 60/031,809, filed July 29, 1996.

FIELD OF THE INVENTION

The invention relates to methods of detecting nucleic

15   acids, whether natural or synthetic, and whether modified or

unmodified. This invention also relates to methods of

nanofabrication. Finally, the invention relates to methods

of separating a selected nucleic acid from other nucleic

acids.

20

BACKGROUND OF THE INVENTION

The development of methods for detecting and sequencing

nucleic acids is critical to the diagnosis of genetic,

bacterial, and viral diseases. *See* Mansfield, E.S. et al.

25   *Molecular and Cellular Probes*, 9, 145-156 (1995). At

present, there are a variety of methods used for detecting

specific nucleic acid sequences. *Id.* However, these

methods are complicated, time-consuming and/or require the

use of specialized and expensive equipment. A simple, fast

30   method of detecting nucleic acids which does not require the

use of such equipment would clearly be desirable.

A variety of methods have been developed for assembling metal and semiconductor colloids into nanomaterials. These methods have focused on the use of covalent linker molecules that possess functionalities at opposing ends with chemical

5 affinities for the colloids of interest. One of the most successful approaches to date, Brust et al., *Adv. Mater.*, **7**, 795-797 (1995), involves the use of gold colloids and well-established thiol adsorption chemistry, Bain & Whitesides, *Angew. Chem. Int. Ed. Engl.*, **28**, 506-512 (1989) and Dubois &

10 Nuzzo, *Annu. Rev. Phys. Chem.*, **43**, 437-464 (1992). In this approach, linear alkanedithiols are used as the particle linker molecules. The thiol groups at each end of the linker molecule covalently attach themselves to the colloidal particles to form aggregate structures. The

15 drawbacks of this method are that the process is difficult to control and the assemblies are formed irreversibly. Methods for systematically controlling the assembly process are needed if the materials properties of these structures are to be exploited fully.

20 The potential utility of DNA for the preparation of biomaterials and in nanofabrication methods has been recognized. In this work, researchers have focused on using the sequence-specific molecular recognition properties of oligonucleotides to design impressive structures with well-

25 defined geometric shapes and sizes. Shekhtman et al., *New J. Chem.*, **17**, 757-763 (1993); Shaw & Wang, *Science*, **260**, 533-536 (1993); Chen et al., *J. Am Chem. Soc.*, **111**, 6402-6407 (1989); Chen & Seeman, *Nature*, **350**, 631-633 (1991); Smith and Feigon, *Nature*, **356**, 164-168 (1992); Wang et al.,

2

Biochem., **32**, 1899-1904 (1993); Chen et al., Biochem., **33**, 13540-13546 (1994); Marsh et al., Nucleic Acids Res., **23**, 696-700 (1995); Mirkin, Annu. Review Biophys. Biomol. Struct., **23**, 541-576 (1994); Wells, J. Biol. Chem., **263**, 1095-1098 (1988); Wang et al., Biochem., **30**, 5667-5674 (1991). However, the theory of producing DNA structures is well ahead of experimental confirmation. Seeman et al., New J. Chem., **17**, 739-755 (1993).

SUMMARY OF THE INVENTION

The invention provides methods of detecting nucleic acids. In one embodiment, the method comprises contacting a nucleic acid with a type of nanoparticles having oligonucleotides attached thereto (nanoparticle-oligonucleotide conjugates). The nucleic acid has at least two portions, and the oligonucleotides on each nanoparticle have a sequence complementary to the sequences of at least two portions of the nucleic acid. The contacting takes place under conditions effective to allow hybridization of the oligonucleotides on the nanoparticles with the nucleic acid. The hybridization of the oligonucleotides on the nanoparticles with the nucleic acid results in a detectable change.

In another embodiment, the method comprises contacting a nucleic acid with at least two types of nanoparticles having oligonucleotides attached thereto. The oligonucleotides on the first type of nanoparticles have a sequence complementary to a first portion of the sequence of the nucleic acid. The oligonucleotides on the second type

of nanoparticles have a sequence complementary to a second
portion of the sequence of the nucleic acid. The contacting
takes place under conditions effective to allow
hybridization of the oligonucleotides on the nanoparticles

5   with the nucleic acid, and a detectable change brought about
by this hybridization is observed.

In a further embodiment, the method comprises providing
a substrate having a first type of nanoparticles attached
thereto. The first type of nanoparticles has

10   oligonucleotides attached thereto, and the oligonucleotides
have a sequence complementary to a first portion of the
sequence of a nucleic acid. The substrate is contacted with
the nucleic acid under conditions effective to allow
hybridization of the oligonucleotides on the nanoparticles

15   with the nucleic acid. Then, a second type of nanoparticles
having oligonucleotides attached thereto is provided. The
oligonucleotides have a sequence complementary to one or
more other portions of the sequence of the nucleic acid, and
the nucleic acid bound to the substrate is contacted with

20   the second type of nanoparticle-oligonucleotide conjugates
under conditions effective to allow hybridization of the
oligonucleotides on the second type of nanoparticles with
the nucleic acid. A detectable change may be observable at
this point. The method may further comprise providing a

25   binding oligonucleotide having a selected sequence having at
least two portions, the first portion being complementary to
at least a portion of the sequence of the oligonucleotides
on the second type of nanoparticles. The binding
oligonucleotide is contacted with the second type of

4

nanoparticle-oligonucleotide conjugates bound to the substrate under conditions effective to allow hybridization of the binding oligonucleotide to the oligonucleotides on the nanoparticles. Then, a third type of nanoparticles

5 having oligonucleotides attached thereto, the oligonucleotides having a sequence complementary to the sequence of a second portion of the binding oligonucleotide, is contacted with the binding oligonucleotide bound to the substrate under conditions effective to allow hybridization

10 of the binding oligonucleotide to the oligonucleotides on the nanoparticles. Finally, the detectable change produced by these hybridizations is observed.

In yet another embodiment, the method comprises contacting a nucleic acid with a substrate having

15 oligonucleotides attached thereto, the oligonucleotides having a sequence complementary to a first portion of the sequence of the nucleic acid. The contacting takes place under conditions effective to allow hybridization of the oligonucleotides on the substrate with the nucleic acid.

20 Then, the nucleic acid bound to the substrate is contacted with a first type of nanoparticles having oligonucleotides attached thereto, the oligonucleotides having a sequence complementary to a second portion of the sequence of the nucleic acid. The contacting takes place under conditions

25 effective to allow hybridization of the oligonucleotides on the nanoparticles with the nucleic acid. Next, the first type of nanoparticle-oligonucleotide conjugates bound to the substrate is contacted with a second type of nanoparticles having oligonucleotides attached thereto, the

oligonucleotides on the second type of nanoparticles having a sequence complementary to at least a portion of the sequence of the oligonucleotides on the first type of nanoparticles, the contacting taking place under conditions

5   effective to allow hybridization of the oligonucleotides on the first and second types of nanoparticles. Finally, a detectable change produced by these hybridizations is observed.

In another embodiment, the method comprises contacting

10   a nucleic acid with a substrate having oligonucleotides attached thereto, the oligonucleotides having a sequence complementary to a first portion of the sequence of the nucleic acid. The contacting takes place under conditions effective to allow hybridization of the oligonucleotides on

15   the substrate with the nucleic acid. Then, the nucleic acid bound to the substrate is contacted with liposomes having oligonucleotides attached thereto, the oligonucleotides having a sequence complementary to a portion of the sequence of the nucleic acid. This contacting takes place under

20   conditions effective to allow hybridization of the oligonucleotides on the liposomes with the nucleic acid. Next, the liposome-oligonucleotide conjugates bound to the substrate are contacted with a first type of nanoparticles having at least a first type of oligonucleotides attached

25   thereto. The first type of oligonucleotides have a hydrophobic group attached to the end not attached to the nanoparticles, and the contacting takes place under conditions effective to allow attachment of the oligonucleotides on the nanoparticles to the liposomes as a

6

result of hydrophobic interactions. A detectable change may
be observable at this point. The method may further
comprise contacting the first type of nanoparticle-
oligonucleotide conjugates bound to the liposomes with a
5 second type of nanoparticles having oligonucleotides
attached thereto. The first type of nanoparticles have a
second type of oligonucleotides attached thereto which have
a sequence complementary to at least a portion of the
sequence of the oligonucleotides on the second type of
10 nanoparticles, and the oligonucleotides on the second type
of nanoparticles having a sequence complementary to at least
a portion of the sequence of the second type of
oligonucleotides on the first type of nanoparticles. The
contacting takes place under conditions effective to allow
15 hybridization of the oligonucleotides on the first and
second types of nanoparticles. Then, a detectable change is
observed.

In yet another embodiment, the method comprises
providing nanoparticles having oligonucleotides attached
20 thereto and providing one or more types of binding
oligonucleotides. Each of the binding oligonucleotides has
two portions. The sequence of one portion is complementary
to the sequence of one of the portions of the nucleic acid,
and the sequence of the other portion is complementary to
25 the sequence of the oligonucleotides on the nanoparticles.
The nanoparticle-oligonucleotide conjugates and the binding
oligonucleotides are contacted under conditions effective to
allow hybridization of the oligonucleotides on the
nanoparticles with the binding oligonucleotides. The

7

nucleic acid and the binding oligonucleotides are contacted
under conditions effective to allow hybridization of the
binding oligonucleotides with the nucleic acid. Then, a
detectable change is observed. The nanoparticle-
5 oligonucleotide conjugates may be contacted with the binding
oligonucleotides prior to being contacted with the nucleic
acid, or all three may be contacted simultaneously.

In another embodiment, the method comprises contacting
a nucleic acid with at least two types of particles having
10 oligonucleotides attached thereto. The oligonucleotides on
the first type of particles have a sequence complementary to
a first portion of the sequence of the nucleic acid and have
energy donor molecules on the ends not attached to the
particles. The oligonucleotides on the second type of
15 particles have a sequence complementary to a second portion
of the sequence of the nucleic acid and have energy acceptor
molecules on the ends not attached to the particles. The
contacting takes place under conditions effective to allow
hybridization of the oligonucleotides on the particles with
20 the nucleic acid, and a detectable change brought about by
this hybridization is observed. The energy donor and
acceptor molecules may be fluorescent molecules.

In a further embodiment, the method comprises providing
a type of latex microspheres having oligonucleotides
25 attached thereto. The oligonucleotides have a sequence
complementary to a first portion of the sequence of the
nucleic acid and are labeled with a fluorescent molecule. A
type of gold nanoparticles having oligonucleotides attached
thereto is also provided. These oligonucleotides have a

sequence complementary to a second portion of the sequence
of the nucleic acid. The nucleic acid is contacted with the
latex microspheres and the nanoparticles under conditions
effective to allow hybridization of the oligonucleotides on
5   the latex microspheres and on the nanoparticles with the
nucleic acid. Then, changes in fluorescence, color or both
are observed.

       In another embodiment, the method comprises providing a
first type of metallic or semiconductor nanoparticles having
10   oligonucleotides attached thereto. The oligonucleotides
have a sequence complementary to a first portion of the
sequence of the nucleic acid and are labeled with a
fluorescent molecule. A second type of metallic or
semiconductor nanoparticles having oligonucleotides attached
15   thereto is also provided. These oligonucleotides have a
sequence complementary to a second portion of the sequence
of the nucleic acid and are also labeled with a fluorescent
molecule. The nucleic acid is contacted with the two types
of nanoparticles under conditions effective to allow
20   hybridization of the oligonucleotides on the two types of
nanoparticles with the nucleic acid. Then, changes in
fluorescence are observed.

       In a further embodiment, the method comprises providing
a type of particle having oligonucleotides attached thereto.
25   The oligonucleotides have a first portion and a second
portion, both portions being complementary to portions of
the sequence of the nucleic acid. A type of probe
oligonucleotides comprising a first portion and a second
portion is also provided. The first portion has a sequence

complementary to the first portion of the oligonucleotides
attached to the particles, and both portions are
complementary to portions of the sequence of the nucleic
acid. The probe oligonucleotides are also labeled with a

5   reporter molecule at one end. Then, the particles and the
probe oligonucleotides are contacted under conditions
effective to allow for hybridization of the oligonucleotides
on the particles with the probe oligonucleotides to produce
a satellite probe. Then, the satellite probe is contacted

10   with the nucleic acid under conditions effective to provide
for hybridization of the nucleic acid with the probe
oligonucleotides. The particles are removed and the
reporter molecule detected.

     The invention further provides kits for detecting

15   nucleic acids. In one embodiment, the kit comprises at
least one container, the container holding at least two
types of nanoparticles having oligonucleotides attached
thereto. The oligonucleotides on the first type of
nanoparticles have a sequence complementary to the sequence

20   of a first portion of a nucleic acid. The oligonucleotides
on the second type of nanoparticles have a sequence
complementary to the sequence of a second portion of the
nucleic acid.

     Alternatively, the kit may comprise at least two

25   containers. The first container holds nanoparticles having
oligonucleotides attached thereto which have a sequence
complementary to the sequence of a first portion of a
nucleic acid. The second container holds nanoparticles
having oligonucleotides attached thereto which have a

10

sequence complementary to the sequence of a second portion of the nucleic acid.

In a further embodiment, the kit comprises at least one container. The container holds metallic or semiconductor

5   nanoparticles having oligonucleotides attached thereto. The oligonucleotides have a sequence complementary to portion of a nucleic acid and have fluorescent molecules attached to the ends of the oligonucleotides not attached to the nanoparticles.

10   In yet another embodiment, the kit comprises a substrate, the substrate having attached thereto nanoparticles, the nanoparticles having oligonucleotides attached thereto which have a sequence complementary to the sequence of a first portion of a nucleic acid. The kit also

15   includes a first container holding nanoparticles having oligonucleotides attached thereto which have a sequence complementary to the sequence of a second portion of the nucleic acid. The kit further includes a second container holding a binding oligonucleotide having a selected sequence

20   having at least two portions, the first portion being complementary to at least a portion of the sequence of the oligonucleotides on the nanoparticles in the first container. The kit also includes a third container holding nanoparticles having oligonucleotides attached thereto, the

25   oligonucleotides having a sequence complementary to the sequence of a second portion of the binding oligonucleotide.

In another embodiment, the kit comprises a substrate having oligonucleotides attached thereto which have a sequence complementary to the sequence of a first portion of

11

a nucleic acid, a first container holding nanoparticles
having oligonucleotides attached thereto which have a
sequence complementary to the sequence of a second portion
of the nucleic acid, and a second container holding

5   nanoparticles having oligonucleotides attached thereto which
have a sequence complementary to at least a portion of the
oligonucleotides attached to the nanoparticles in the first
container.

In yet another embodiment, the kit comprises a

10   substrate, a first container holding nanoparticles, a second
container holding a first type of oligonucleotides having a
sequence complementary to the sequence of a first portion of
a nucleic acid, a third container holding a second type of
oligonucleotides having a sequence complementary to the

15   sequence of a second portion of the nucleic acid, and a
fourth container holding a third type of oligonucleotides
having a sequence complementary to at least a portion of the
sequence of the second type of oligonucleotides.

In a further embodiment, the kit comprises a substrate

20   having oligonucleotides attached thereto which have a
sequence complementary to the sequence of a first portion of
a nucleic acid. The kit also includes a first container
holding liposomes having oligonucleotides attached thereto
which have a sequence complementary to the sequence of a

25   second portion of the nucleic acid and a second container
holding nanoparticles having at least a first type of
oligonucleotides attached thereto, the first type of
oligonucleotides having a hydrophobic group attached to the
end not attached to the nanoparticles so that the

12

nanoparticles can be attached to the liposomes by
hydrophobic interactions. The kit may further comprise a
third container holding a second type of nanoparticles
having oligonucleotides attached thereto, the

5   oligonucleotides having a sequence complementary to at least
a portion of the sequence of a second type of
oligonucleotides attached to the first type of
nanoparticles. The second type of oligonucleotides attached
to the first type of nanoparticles have a sequence

10   complementary to the sequence of the oligonucleotides on the
second type of nanoparticles.

In a further embodiment, the kit comprises a first
container holding nanoparticles having oligonucleotides
attached thereto. The kit also includes one or more

15   additional containers, each container holding binding
oligonucleotides. Each binding oligonucleotide has a first
portion which has a sequence complementary to at least a
portion of the sequence of oligonucleotides on the
nanoparticles and a second portion which has a sequence

20   complementary to the sequence of a portion of a nucleic acid
to be detected. The sequences of the second portions of the
binding oligonucleotides may be different as long as each
sequence is complementary to a portion of the sequence of
the nucleic acid to be detected.

25   In yet another embodiment, the kit comprises a
container holding one type of nanoparticles having
oligonucleotides attached thereto and one or more types of
binding oligonucleotides. Each of the types of binding
oligonucleotides has a sequence comprising at least two

portions. The first portion is complementary to the sequence of the oligonucleotides on the nanoparticles, whereby the binding oligonucleotides are hybridized to the oligonucleotides on the nanoparticles in the container(s).

5   The second portion is complementary to the sequence of a portion of the nucleic acid.

In another alternative embodiment, the kit comprises at least three containers. The first container holds nanoparticles. The second container holds a first

10   oligonucleotide having a sequence complementary to the sequence of a first portion of a nucleic acid. The third container holds a second oligonucleotide having a sequence complementary to the sequence of a second portion of the nucleic acid. The kit may further comprise a fourth

15   container holding a binding oligonucleotide having a selected sequence having at least two portions, the first portion being complementary to at least a portion of the sequence of the second oligonucleotide, and a fifth container holding an oligonucleotide having a sequence

20   complementary to the sequence of a second portion of the binding oligonucleotide.

In another embodiment, the kit comprises one or two containers, the container(s) holding two types of particles. The first type of particles having oligonucleotides attached

25   thereto that have a sequence complementary to a first portion of the sequence of a nucleic acid and have energy donor molecules attached to the ends not attached to the nanoparticles. The second type of particles having oligonucleotides attached thereto that have a sequence

14

complementary to a second portion of the sequence of a nucleic acid and have energy acceptor molecules attached to the ends not attached to the nanoparticles. The energy donors and acceptors may be fluorescent molecules.

5   In a further embodiment, the kit comprises a first container holding a type of latex microspheres having oligonucleotides attached thereto. The oligonucleotides have a sequence complementary to a first portion of the sequence of a nucleic acid and are labeled with a

10   fluorescent molecule. The kit also comprises a second container holding a type of gold nanoparticles having oligonucleotides attached thereto. The oligonucleotides have a sequence complementary to a second portion of the sequence of the nucleic acid.

15   In another embodiment, the kit comprises a first container holding a first type of metallic or semiconductor nanoparticles having oligonucleotides attached thereto. The oligonucleotides have a sequence complementary to a first portion of the sequence of a nucleic acid and are labeled

20   with a fluorescent molecule. The kit also comprises a second container holding a second type of metallic or semiconductor nanoparticles having oligonucleotides attached thereto. These oligonucleotides have a sequence complementary to a second portion of the sequence of a

25   nucleic acid and are labeled with a fluorescent molecule.

In a further embodiment, the kit comprises a container holding a satellite probe. The satellite probe comprises a particle having attached thereto oligonucleotides. The oligonucleotides have a first portion and a second portion,

15

both portions having sequences complementary to portions of the sequence of a nucleic acid. The satellite probe also comprises probe oligonucleotides hybridized to the oligonucleotides attached to the nanoparticles. The probe

5   oligonucleotides have a first portion and a second portion. The first portion has a sequence complementary to the sequence of the first portion of the oligonucleotides attached to the particles, and both portions have sequences complementary to portions of the sequence of the nucleic

10   acid. The probe oligonucleotides also have a reporter molecule attached to one end.

The invention also provides the satellite probe.

The invention further provides a substrate having nanoparticles attached thereto. The nanoparticles may have

15   oligonucleotides attached thereto which have a sequence complementary to the sequence of a first portion of a nucleic acid.

The invention also provides a metallic or semiconductor nanoparticle having oligonucleotides attached thereto. The

20   oligonucleotides are labeled with fluorescent molecules at the ends not attached to the nanoparticle.

The invention further provides a method of nanofabrication. The method comprises providing at least one type of linking oligonucleotide having a selected

25   sequence, the sequence of each type of linking oligonucleotide having at least two portions. The method further comprises providing one or more types of nanoparticles having oligonucleotides attached thereto, the oligonucleotides on each type of nanoparticles having a

16

sequence complementary to a portion of the sequence of a linking oligonucleotide. The linking oligonucleotides and nanoparticles are contacted under conditions effective to allow hybridization of the oligonucleotides on the
5   nanoparticles to the linking oligonucleotides so that a desired nanomaterial or nanostructure is formed.

The invention provides another method of nanofabrication. This method comprises providing at least two types of nanoparticles having oligonucleotides attached
10   thereto. The oligonucleotides on the first type of nanoparticles have a sequence complementary to that of the oligonucleotides on the second type of nanoparticles. The oligonucleotides on the second type of nanoparticles have a sequence complementary to that of the oligonucleotides on
15   the first type of nanoparticle-oligonucleotide conjugates. The first and second types of nanoparticles are contacted under conditions effective to allow hybridization of the oligonucleotides on the nanoparticles to each other so that a desired nanomaterial or nanostructure is formed.

20   The invention further provides nanomaterials or nanostructures composed of nanoparticles having oligonucleotides attached thereto, the nanoparticles being held together by oligonucleotide connectors.

The invention also provides a composition comprising at
25   least two types of nanoparticles having oligonucleotides attached thereto. The oligonucleotides on the first type of nanoparticles have a sequence complementary to the sequence of a first portion of a nucleic acid or a linking oligonucleotide. The oligonucleotides on the second type of

17

nanoparticles have a sequence complementary to the sequence of a second portion of the nucleic acid or linking oligonucleotide.

The invention further provides an assembly of

5   containers comprising a first container holding nanoparticles having oligonucleotides attached thereto, and a second container holding nanoparticles having oligonucleotides attached thereto. The oligonucleotides attached to the nanoparticles in the first container have a

10   sequence complementary to that of the oligonucleotides attached to the nanoparticles in the second container. The oligonucleotides attached to the nanoparticles in the second container have a sequence complementary to that of the oligonucleotides attached to the nanoparticles in the first

15   container.

The invention also provides a nanoparticle having a plurality of different oligonucleotides attached to it.

Finally, the invention provides a method of separating a selected nucleic acid having at least two portions from

20   other nucleic acids. The method comprises providing one or more types of nanoparticles having oligonucleotides attached thereto, the oligonucleotides on each of the types of nanoparticles having a sequence complementary to the sequence of one of the portions of the selected nucleic

25   acid. The selected nucleic acid and other nucleic acids are contacted with the nanoparticles under conditions effective to allow hybridization of the oligonucleotides on the nanoparticles with the selected nucleic acid so that the

nanoparticles hybridized to the selected nucleic acid
aggregate and precipitate.

　　　　As used herein, a "type of oligonucleotides" refers to
a plurality of oligonucleotide molecules having the same
5　　　sequence. A "type of" nanoparticles, particles, latex
microspheres, etc. having oligonucleotides attached thereto
refers to a plurality of nanoparticles having the same
type(s) of oligonucleotides attached to them.
"Nanoparticles having oligonucleotides attached thereto" are
10　　also sometimes referred to as "nanoparticle-oligonucleotide
conjugates" or, in the case of the detection methods of the
invention, "nanoparticle-oligonucleotide probes,"
"nanoparticle probes," or just "probes."

15　　　　　　　　BRIEF DESCRIPTION OF THE DRAWINGS
　　　　Figure 1: Schematic diagram illustrating the formation
of nanoparticle aggregates by combining nanoparticles having
complementary oligonucleotides attached to them, the
nanoparticles being held together in the aggregates as a
20　　result of the hybridization of the complementary
oligonucleotides. X represents any covalent anchor (such as
$-S(CH_2)_3OP(O)(O^-)-$, where S is joined to a gold
nanoparticle). For the sake of simplicity in Figure 1 and
some subsequent figures, only one oligonucleotide is shown
25　　to be attached to each particle but, in fact, each particle
has several oligonucleotides attached to it. Also, it is
important to note that in Figure 1 and subsequent figures,
the relative sizes of the gold nanoparticles and the
oligonucleotides are not drawn to scale.

Figure 2: Schematic diagram illustrating a system for detecting nucleic acid using nanoparticles having oligonucleotides attached thereto. The oligonucleotides on the two nanoparticles have sequences complementary to two
5   different portions of the single-stranded DNA shown. As a consequence, they hybridize to the DNA producing detectable changes (forming aggregates and producing a color change).

Figure 3: Schematic diagram of a variation of the system shown in Figure 2. The oligonucleotides on the two
10   nanoparticles have sequences complementary to two different portions of the single-stranded DNA shown which are separated by a third portion which is not complementary to the oligonucleotides on the nanoparticles. Also shown is an optional filler oligonucleotide which can be used to
15   hybridize with the noncomplementary portion of the single-stranded DNA. When the DNA, nanoparticles and filler oligonucleotides are combined, the nanoparticles aggregate, with the formation of nicked, double-stranded oligonucleotide connectors.

20   Figure 4: Schematic diagram illustrating reversible aggregation of nanoparticles having oligonucleotides attached thereto as a result of hybridization and de-hybridization with a linking oligonucleotide. The illustrated linking oligonucleotide is a double-stranded DNA
25   having overhanging termini (sticky ends) which are complementary to the oligonucleotides attached to the nanoparticles.

Figure 5: Schematic diagram illustrating the formation of nanoparticle aggregates by combining nanoparticles having

20

oligonucleotides attached thereto with linking
oligonucleotides having sequences complementary to the
oligonucleotides attached to the nanoparticles.

Figure 6: Cuvettes containing two types of gold
5   colloids, each having a different oligonucleotide attached
thereto and a linking double-stranded oligonucleotide with
sticky ends complementary to the oligonucleotides attached
to the nanoparticles (see Figure 4). Cuvette A - at 80°C,
which is above the Tm of the linking DNA; de-hybridized
10   (thermally denatured). The color is dark red. Cuvette B -
after cooling to room temperature, which is below the Tm of
the linking DNA; hybridization has taken place, and the
nanoparticles have aggregated, but the aggregates have not
precipitated. The color is purple. Cuvette C - after
15   several hours at room temperature, the aggregated
nanoparticles have settled to the bottom of the cuvette.
The solution is clear, and the precipitate is pinkish gray.
Heating B or C will result in A.

Figure 7: A graph of absorbance versus wavelength in
20   nm showing changes in absorbance when gold nanoparticles
having oligonucleotides attached thereto aggregate due to
hybridization with linking oligonucleotides upon lowering of
the temperature, as illustrated in Figure 4.

Figures 8A-B: Figure 8A is a graph of change in
25   absorbance versus temperature/time for the system
illustrated in Figure 4. At low temperatures, gold
nanoparticles having oligonucleotides attached thereto
aggregate due to hybridization with linking oligonucleotides
(see Figure 4). At high temperature (80°C), the

21

nanoparticles are de-hybridized. Changing the temperature
over time shows that this is a reversible process. Figure
8B is a graph of change in absorbance versus
temperature/time performed in the same manner using an
5   aqueous solution of unmodified gold nanoparticles. The
reversible changes seen in Figure 8A are not observed.

Figures 9A-B: Transmission Electron Microscope (TEM)
images. Figure 9A is a TEM image of aggregated gold
nanoparticles held together by hybridization of the
10   oligonucleotides on the gold nanoparticles with linking
oligonucleotides. Figure 9B is a TEM image of a two-
dimensional aggregate showing the ordering of the linked
nanoparticles.

Figure 10: Schematic diagram illustrating the
15   formation of thermally-stable triple-stranded
oligonucleotide connectors between nanoparticles having the
pyrimidine:purine:pyrimidine motif. Such triple-stranded
connectors are stiffer than double-stranded connectors. In
Figure 10, one nanoparticle has an oligonucleotide attached
20   to it which is composed of all purines, and the other
nanoparticle has an oligonucleotide attached to it which is
composed of all pyrimidines. The third oligonucleotide for
forming the triple-stranded connector (not attached to a
nanoparticle) is composed of pyrimidines.

25   Figure 11: Schematic diagram illustrating the
formation of nanoparticle aggregates by combining
nanoparticles having complementary oligonucleotides attached
to them, the nanoparticles being held together in the
aggregates as a result of the hybridization of the

22

complementary oligonucleotides. In Figure 11, the circles represent the nanoparticles, the formulas are oligonucleotide sequences, and s is the thio-alkyl linker. The multiple oligonucleotides on the two types of nanoparticles can hybridize to each other, leading to the formation of an aggregate structure.

Figures 12A-F: Schematic diagrams illustrating systems for detecting nucleic acid using nanoparticles having oligonucleotides attached thereto. Oligonucleotide-nanoparticle conjugates 1 and 2 and single-stranded oligonucleotide targets 3, 4, 5, 6 and 7 are illustrated. The circles represent the nanoparticles, the formulas are oligonucleotide sequences, and the dotted and dashed lines represent connecting links of nucleotide.

Figures 13A-B: Schematic diagrams illustrating systems for detecting DNA (analyte DNA) using nanoparticles and a transparent substrate.

Figures 14A-B: Figure 14A is a graph of absorbance versus wavelength in nm showing changes in absorbance when gold nanoparticles having oligonucleotides attached thereto (one population of which is in solution and one population of which is attached to a transparent substrate as illustrated in Figure 13B) aggregate due to hybridization with linking oligonucleotides. Figure 14B a graph of change in absorbance for the hybridized system referred to in Figure 14A as the temperature is increased (melted).

Figures 15A-G: Schematic diagrams illustrating systems for detecting nucleic acid using nanoparticles having oligonucleotides attached thereto. Oligonucleotide-

23

nanoparticle conjugates 1 and 2 and single-stranded
oligonucleotide targets 3, 4, 5, 6, 7 and 8 are illustrated.
The circles represent the nanoparticles, the formulas are
oligonucleotide sequences, and S represents the thio-alkyl
5   linker.

Figures 16A-C: Schematic diagrams illustrating systems
for detecting nucleic acid using nanoparticles having
oligonucleotides attached thereto. Oligonucleotide-
nanoparticle conjugates 1 and 2, single-stranded
10   oligonucleotide targets of different lengths, and filler
oligonucleotides of different lengths are illustrated. The
circles represent the nanoparticles, the formulas are
oligonucleotide sequences, and S represents the thio-alkyl
linker.

15   Figures 17A-E: Schematic diagrams illustrating
nanoparticle-oligonucleotide conjugates and systems for
detecting nucleic acid using nanoparticles having
oligonucleotides attached thereto. The circles represent
the nanoparticles, the straight lines represent
20   oligonucleotide chains (bases not shown), two closely-spaced
parallel lines represent duplex segments, and the small
letters indicate specific nucleotide sequences (a is
complementary to a', b is complementary to b', etc.).

Figure 18: Schematic diagram illustrating a system for
25   detecting nucleic acid using liposomes (large double
circle), nanoparticles (small open circles) and a
transparent substrate. The filled-in squares represent
cholesteryl groups, the squiggles represent

oligonucleotides, and the ladders represent double-stranded (hybridized) oligonucleotides.

Figures 19A-B: Figure 19A is a graph of absorbance versus wavelength in nm showing changes in absorbance when gold nanoparticle-oligonucleotide conjugates assemble in multiple layers on a transparent substrate as illustrated in Figure 13A. Figure 19B is a graph of change in absorbance for the hybridized system referred to in Figure 19A as the temperature is increased (melted).

Figures 20A-B: Illustrations of schemes using fluorescent-labeled oligonucleotides attached to metallic or semiconductor quenching nanoparticles (Figure 20A) or to non-metallic, non-semiconductor particles (Figure 20B).

Figure 21: Schematic diagram illustrating a system for detecting target nucleic acid using gold nanoparticles having oligonucleotides attached thereto and latex microspheres having fluorescently-labeled oligonucleotides attached thereto. The small, closed, dark circles represent the nanoparticles, the large, open circles represent the latex microspheres, and the large oval represents a microporous membrane.

Figure 22: Schematic diagram illustrating a system for detecting target nucleic acid using two types of fluorescently-labeled oligonucleotide-nanoparticle conjugates. The closed circles represent the nanoparticles, and the large oval represents a microporous membrane.

Figure 23: Sequences of materials utilized in an assay for Anthrax Protective Antigen (see Example 12).

Figure 24: Schematic diagram illustrating a system for detecting target nucleic acid using a "satellite probe" which comprises magnetic nanoparticles (dark spheres) having oligonucleotides (straight lines) attached to them, probe
5 oligonucleotides (strainght lines) hybridized to the oligonucleotides attached to the nanoparticles, the probe oligonucleotides being labeled with a reporter group (open rectangular box). A, B, C, A', B', and C' represent specific nucleotide sequences, with A, B and C being
10 complementary to A', B' and C', respectively.

DETAILED DESCRIPTION OF THE
PRESENTLY PREFERRED EMBODIMENTS

Nanoparticles useful in the practice of the invention
15 include metal (e.g., gold, silver, copper and platinum), semiconductor (e.g., CdSe, CdS, and CdS coated with ZnS) and magnetic (e.g., ferromagnetite) colloidal materials. Other nanoparticles useful in the practice of the invention include ZnS, ZnO, TiO_2, AgI, AgBr, HgI_2, PbS, PbSe, ZnTe,
20 CdTe, In_2S_3, In_2Se_3, Cd_3P_2, Cd_3As_2, InAs, and GaAs. The size of the nanoparticles is preferably from about 5 nm to about 150 nm (mean diameter), more preferably from about 5 to about 50 nm, most preferably from about 10 to about 30 nm.

Methods of making metal, semiconductor and magnetic
25 nanoparticles are well-known in the art. See, e.g., Schmid, G. (ed.) Clusters and Colloids (VCH, Weinheim, 1994); Hayat, M.A. (ed.) Colloidal Gold: Principles, Methods, and Applications (Academic Press, San Diego, 1991); Massart, R., IEEE Taransactions On Magnetics, 17, 1247 (1981); Ahmadi,

26

T.S. et al., *Science*, **272**, 1924 (1996); Henglein, A. et al., *J. Phys. Chem.*, **99**, 14129 (1995); Curtis, A.C., et al., *Angew. Chem. Int. Ed. Engl.*, **27**, 1530 (1988).

5   Methods of making ZnS, ZnO, TiO_2, AgI, AgBr, HgI_2, PbS, PbSe, ZnTe, CdTe, In_2S_3, In_2Se_3, Cd_3P_2, Cd_3As_2, InAs, and GaAs nanoparticles are also known in the art. See, *e.g.*, Weller, *Angew. Chem. Int. Ed. Engl.*, **32**, 41 (1993); Henglein, *Top. Curr. Chem.*, **143**, 113 (1988); Henglein, *Chem. Rev.*, **89**, 1861 (1989); Brus, *Appl. Phys. A.*, **53**, 465 (1991); Bahncmann, in

10   Photochemical Conversion and Storage of Solar Energy (eds. Pelizetti and Schiavello 1991), page 251; Wang and Herron, *J. Phys. Chem.*, **95**, 525 (1991); Olshavsky et al., *J. Am. Chem. Soc.*, **112**, 9438 (1990); Ushida et al., *J. Phys. Chem.*, **95**, 5382 (1992).

15   Suitable nanoparticles are also commercially available from, *e.g.*, Ted Pella, Inc. (gold), Amersham Corporatrion (gold) and Nanoprobes, Inc. (gold).

Presently preferred for use in detecting nucleic acids are gold nanoparticles. Gold colloidal particles have high

20   extinction coefficients for the bands that give rise to their beautiful colors. These intense colors change with particle size, concentration, interparticle distance, and extent of aggregation and shape (geometry) of the aggregates, making these materials particularly attractive

25   for colorimetric assays. For instance, hybridization of oligonucleotides attached to gold nanoparticles with oligonucleotides and nucleic acids results in an immediate color change visible to the naked eye (see, *e.g.*, the Examples).

27

Gold nanoparticles are also presently preferred for use in nanofabrication for the same reasons given above and because of their stability, ease of imaging by electron microscopy, and well-characterized modification with thiol
5   functionalities (see below).

The nanoparticles, the oligonucleotides or both are functionalized in order to attach the oligonucleotides to the nanoparticles. Such methods are known in the art. For instance, oligonucleotides functionalized with alkanethiols
10   at their 3'-termini or 5'-termini readily attach to gold nanoparticles. See Whitesides, *Proceedings of the Robert A. Welch Foundation 39th Conference On Chemical Research Nanophase Chemistry*, Houston, TX, pages 109-121 (1995). See also, Mucic et al. *Chem. Commun.* 555-557 (1996) (describes
15   a method of attaching 3' thiol DNA to flat gold surfaces; this method can be used to attach oligonucleotides to nanoparticles). The alkanethiol method can also be used to attach oligonucleotides to other metal, semiconductor and magnetic colloids and to the other nanoparticles listed
20   above. Other functional groups for attaching oligonucleotides to solid surfaces include phosphorothioate groups (see, *e.g.*, U.S. Patent No. 5,472,881 for the binding of oligonucleotide-phosphorothioates to gold surfaces), substituted alkylsiloxanes (see, *e.g.* Burwell, *Chemical*
25   *Technology*, **4**, 370-377 (1974) and Matteucci and Caruthers, *J. Am. Chem. Soc.*, **103**, 3185-3191 (1981) for binding of oligonucleotides to silica and glass surfaces, and Grabar et al., *Anal. Chem.*, **67**, 735-743 for binding of aminoalkylsiloxanes and for similar binding of

28

mercaptoaklylsiloxanes). Oligonucleotides terminated with a
5' thionucleoside or a 3' thionucleoside may also be used
for attaching oligonucleotides to solid surfaces. Gold
nanoparticles may be attached to oligonucleotides using

5 biotin-labeled oligonucleotides and streptavidin-gold
conjugate colloids; the biotin-streptavidin interaction
attaches the colloids to the oligonucleotide. Shaiu et al.,
Nuc. Acids Res., **21**, 99 (1993). The following references
describe other methods which may be employed to attached

10 oligonucleotides to nanoparticles: Nuzzo et al., *J. Am.
Chem. Soc.*, **109**, 2358 (1987) (disulfides on gold); Allara
and Nuzzo, *Langmuir*, **1**, 45 (1985) (carboxylic acids on
aluminum); Allara and Tompkins, *J. Colloid Interface Sci.*,
49, 410-421 (1974) (carboxylic acids on copper); Iler, The

15 Chemistry Of Silica, Chapter 6, (Wiley 1979) (carboxylic
acids on silica); Timmons and Zisman, *J. Phys. Chem.*, **69**,
984-990 (1965) (carboxylic acids on platinum); Soriaga and
Hubbard, *J. Am. Chem. Soc.*, **104**, 3937 (1982) (aromatic ring
compounds on platinum); Hubbard, *Acc. Chem. Res.*, **13**, 177

20 (1980) (sulfolanes, sulfoxides and other functionalized
solvents on platinum); Hickman et al., *J. Am. Chem. Soc.*,
111, 7271 (1989) (isonitriles on platinum); Maoz and Sagiv,
Langmuir, **3**, 1045 (1987) (silanes on silica); Maoz and
Sagiv, *Langmuir*, **3**, 1034 (1987) (silanes on silica);

25 Wasserman et al., *Langmuir*, **5**, 1074 (1989) (silanes on
silica); Eltekova and Eltekov, *Langmuir*, **3**, 951 (1987)
(aromatic carboxylic acids, aldehydes, alcohols and methoxy
groups on titanium dioxide and silica); Lec et al., *J. Phys.
Chem.*, **92**, 2597 (1988) (rigid phosphates on metals).

29

Each nanoparticle will have a plurality of
oligonucleotides attached to it. As a result, each
nanoparticle-oligonucleotide conjugate can bind to a
plurality of oligonucleotides or nucleic acids having the
5   complementary sequence.

Oligonucleotides of defined sequences are used for a
variety of purposes in the practice of the invention.
Methods of making oligonucleotides of a predetermined
sequence are well-known. See, *e.g.*, Sambrook *et al.*,
10   *Molecular Cloning: A Laboratory Manual* (2nd ed. 1989) and
F. Eckstein (ed.) *Oligonucleotides and Analogues*, 1st Ed.
(Oxford University Press, New York, 1991). Solid-phase
synthesis methods are preferred for both
oligoribonucleotides and oligodeoxyribonucleotides (the
15   well-known methods of synthesizing DNA are also useful for
synthesizing RNA). Oligoribonucleotides and
oligodeoxyribonucleotides can also be prepared
enzymatically.

The invention provides methods of detecting nucleic
20   acids. Any type of nucleic acid may be detected, and the
methods may be used, *e.g.*, for the diagnosis of disease and
in sequencing of nucleic acids. Examples of nucleic acids
that can be detected by the methods of the invention include
genes (*e.g.*, a gene associated with a particular disease),
25   viral RNA and DNA, bacterial DNA, fungal DNA, cDNA, mRNA,
RNA and DNA fragments, oligonucleotides, synthetic
oligonucleotides, modified oligonucleotides, single-stranded
and double-stranded nucleic acids, natural and synthetic
nucleic acids, etc. Thus, examples of the uses of the

methods of detecting nucleic acids include: the diagnosis and/or monitoring of viral diseases (e.g., human immunodeficiency virus, hepatitis viruses, herpes viruses, cytomegalovirus, and Epstein-Barr virus), bacterial diseases

5   (e.g., tuberculosis, Lyme disease, H. pylori, Escherichia coli infections, Legionella infections, Mycoplasma infections, Salmonella infections), sexually transmitted diseases (e.g., gonorrhoea), inherited disorders (e.g., cystic fibrosis, Duchene muscular dystrophy,

10   phenylketonuria, sickle cell anemia), and cancers (e.g., genes associated with the development of cancer); in forensics; in DNA sequencing; for paternity testing; for cell line authentication; for monitoring gene therapy; and for many other purposes.

15   The methods of detecting nucleic acids based on observing a color change with the naked eye are cheap, fast, simple, robust (the reagents are stable), do not require specialized or expensive equipment, and little or no instrumentation is required. This makes them particularly

20   suitable for use in, e.g., research and analytical laboratories in DNA sequencing, in the field to detect the presence of specific pathogens, in the doctor's office for quick identification of an infection to assist in prescribing a drug for treatment, and in homes and health

25   centers for inexpensive first-line screening.

The nucleic acid to be detected may be isolated by known methods, or may be detected directly in cells, tissue samples, biological fluids (e.g., saliva, urine, blood, serum), solutions containing PCR components, solutions

31

containing large excesses of oligonucleotides or high molecular weight DNA, and other samples, as also known in the art. See, *e.g.*, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual* (2nd ed. 1989) and B.D. Hames and S.J.

5   Higgins, Eds., *Gene Probes 1* (IRL Press, New York, 1995). Methods of preparing nucleic acids for detection with hybridizing probes are well known in the art. See, *e.g.*, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual* (2nd ed. 1989) and B.D. Hames and S.J. Higgins, Eds., *Gene*

10 *Probes 1* (IRL Press, New York, 1995).

If a nucleic acid is present in small amounts, it may be amplifed by methods known in the art. See, *e.g.*, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual* (2nd ed. 1989) and B.D. Hames and S.J. Higgins, Eds., *Gene*

15 *Probes 1* (IRL Press, New York, 1995). Preferred is polymerase chain reaction (PCR) amplification.

One method according to the invention for detecting nucleic acid comprises contacting a nucleic acid with one or more types of nanoparticles having oligonucleotides attached

20 thereto. The nucleic acid to be detected has at least two portions. The lengths of these portions and the distance(s), if any, between them are chosen so that when the oligonucleotides on the nanoparticles hybridize to the nucleic acid, a detectable change occurs. These lengths and

25 distances can be determined empirically and will depend on the type of particle used and its size and the type of electrolyte which will be present in solutions used in the assay (as is known in the art, certain electrolytes affect the conformation of nucleic acids).

32

Also, when a nucleic acid is to be detected in the presence of other nucleic acids, the portions of the nucleic acid to which the oligonucleotides on the nanoparticles are to bind must be chosen so that they contain sufficient

5   unique sequence so that detection of the nucleic acid will be specific. Guidelines for doing so are well known in the art.

Although nucleic acids may contain repeating sequences close enough to each other so that only one type of

10   oligonucleotide-nanoparticle conjugate need be used, this will be a rare occurrence. In general, the chosen portions of the nucleic acid will have different sequences and will be contacted with nanoparticles carrying two or more different oligonucleotides, preferably attached to different

15   nanoparticles. An example of a system for the detection of nucleic acid is illustrated in Figure 2. As can be seen, a first oligonucleotide attached to a first nanoparticle has a sequence complementary to a first portion of the target sequence in the single-stranded DNA. A second

20   oligonucleotide attached to a second nanoparticle has a sequence complementary to a second portion of the target sequence in the DNA. Additional portions of the DNA could be targeted with corresponding nanoparticles. See Figure 17. Targeting several portions of a nucleic acid increases

25   the magnitude of the detectable change.

The contacting of the nanoparticle-oligonucleotide conjugates with the nucleic acid takes place under conditions effective for hybridization of the oligonucleotides on the nanoparticles with the target

sequence(s) of the nucleic acid. These hybridization conditions are well known in the art and can readily be optimized for the particular system employed. See, *e.g.*, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*

5   (2nd ed. 1989). Preferably stringent hybridization conditions are employed.

Faster hybridization can be obtained by freezing and thawing a solution containing the nucleic acid to be detected and the nanoparticle-oligonucleotide conjugates.

10   The solution may be frozen in any convenient manner, such as placing it in a dry ice-alcohol bath for a sufficient time for the solution to freeze (generally about 1 minute for 100 μL of solution). The solution must be thawed at a temperature below the thermal denaturation temperature,

15   which can conveniently be room temperature for most combinations of nanoparticle-oligonucleotide conjugates and nucleic acids. The hybridization is complete, and the detectable change may be observed, after thawing the solution.

20   The rate of hybridization can also be increased by warming the solution containing the nucleic acid to be detected and the nanoparticle-oligonucleotide conjugates to a temperature below the dissociation temperature (Tm) for the complex formed between the oligonucleotides on the

25   nanoparticles and the target nucleic acid. Alternatively, rapid hybridization can be achieved by heating above the dissociation temperature (Tm) and allowing the solution to cool.

34

The rate of hybridization can also be increased by increasing the salt concentration (*e.g.*, from 0.1 M to 0.3 M NaCl).

The detectable change that occurs upon hybridization of
5 the oligonucleotides on the nanoparticles to the nucleic acid may be a color change, the formation of aggregates of the nanoparticles, or the precipitation of the aggregated nanoparticles. The color changes can be observed with the naked eye or spectroscopically. The formation of aggregates
10 of the nanoparticles can be observed by electron microscopy or by nephelometry. The precipitation of the aggregated nanoparticles can be observed with the naked eye or microscopically. Preferred are changes observable with the naked eye. Particularly preferred is a color change
15 observable with the naked eye.

The observation of a color change with the naked eye can be made more readily against a background of a contrasting color. For instance, when gold nanoparticles are used, the observation of a color change is facilitated
20 by spotting a sample of the hybridization solution on a solid white surface (such as silica or alumina TLC plates, filter paper, cellulose nitrate membranes, and nylon membranes, preferably a C-18 silica TLC plate) and allowing the spot to dry. Initially, the spot retains the color of
25 the hybridization solution (which ranges from pink/red, in the absence of hybridization, to purplish-red/purple, if there has been hybridization). On drying at room temperature or 80°C (temperature is not critical), a blue spot develops if the nanoparticle-oligonucleotide conjugates

35

had been linked by hybridization with the target nucleic
acid prior to spotting. In the absence of hybridization
(e.g., because no target nucleic acid is present), the spot
is pink. The blue and the pink spots are stable and do not

5   change on subsequent cooling or heating or over time. They
provide a convenient permanent record of the test. No other
steps (such as a separation of hybridized and unhybridized
nanoparticle-oligonucleotide conjugates) are necessary to
observe the color change.

10   An alternate method for easily visualizing the assay
results is to spot a sample of nanoparticle probes
hybridized to a target nucleic acid on a glass fiber filter
(e.g., Borosilicate Microfiber Filter, 0.7 micron pore size,
grade FG75, for use with gold nanoparticles 13 nm in size),

15   while drawing the liquid through the filter. Subsequent
rinsing with water washes the excess, non-hybridized probes
through the filter, leaving behind an observable spot
comprising the aggregates generated by hybridization of the
nanoparticle probes with the target nucleic acid (retained

20   because these aggregates are larger than the pores of the
filter). This technique may provide for greater
sensitivity, since an excess of nanoparticle probes can be
used. Unfortunately, the nanoparticle probes stick to many
other solid surfaces that have been tried (silica slides,

25   reverse-phase plates, and nylon, nitrocellulose, cellulose
and other membranes), and these surfaces cannot be used.

        An important aspect of the detection system illustrated
in Figure 2 is that obtaining a detectable change depends on
cooperative hybridization of two different oligonucleotides

to a given target sequence in the nucleic acid. Mismatches
in either of the two oligonucleotides will destabilize the
interparticle connection. It is well known that a mismatch
in base pairing has a much greater destabilizing effect on
5   the binding of a short oligonucleotide probe than on the
binding of a long oligonucleotide probe. The advantage of
the system illustrated in Figure 2 is that it utilizes the
base discrimination associated with a long target sequence
and probe (eighteen base-pairs in the example illustrated in
10   Figure 2), yet has the sensitivity characteristic of a short
oligonucleotide probe (nine base-pairs in the example
illustrated in Figure 2).

The target sequence of the nucleic acid may be
contiguous, as in Figure 2, or the two portions of the
15   target sequence may be separated by a third portion which is
not complementary to the oligonucleotides on the
nanoparticles, as illustrated in Figure 3. In the latter
case, one has the option of using a filler oligonucleotide
which is free in solution and which has a sequence
20   complementary to that of this third portion (see Figure 3).
When the filler oligonucleotide hybridizes with the third
portion of the nucleic acid, a double-stranded segment is
created, thereby altering the average distance between the
nanoparticles and, consequently, the color. The system
25   illustrated in Figure 3 may increase the sensitivity of the
detection method.

Some embodiments of the method of detecting nucleic
acid utilize a substrate. By employing a substrate, the

37

detectable change (the signal) can be amplified and the sensitivity of the assay increased.

Any substrate can be used which allows observation of the detectable change. Suitable substrates include

5   transparent solid surfaces (*e.g.*, glass, quartz, plastics and other polymers), opaque solid surface (*e.g.*, white solid surfaces, such as TLC silica plates, filter paper, glass fiber filters, cellulose nitrate membranes, nylon membranes), and conducting solid surfaces (*e.g.*, indium-tin-

10   oxide (ITO)). The substrate can be any shape or thickness, but generally will be flat and thin. Preferred are transparent substrates such as glass (*e.g.*, glass slides) or plastics (*e.g.*, wells of microtiter plates).

In one embodiment, oligonucleotides are attached to the

15   substrate. The oligonucleotides can be attached to the substrates as described in, *e.g.*, Chrisey et al., *Nucleic Acids Res.*, **24**, 3031-3039 (1996); Chrisey et al., *Nucleic Acids Res.*, **24**, 3040-3047 (1996); Mucic et al., *Chem. Commun.*, **555** (1996); Zimmermann and Cox, *Nucleic Acids Res.*,

20   **22**, 492 (1994); Bottomley et al., *J. Vac. Sci. Technol. A,* **10**, 591 (1992); and Hegner et al., *FEBS Lett.*, **336**, 452 (1993).

The oligonucleotides attached to the substrate have a sequence complementary to a first portion of the sequence of

25   the nucleic acid to be detected. The nucleic acid is contacted with the substrate under conditions effective to allow hybridization of the oligonucleotides on the substrate with the nucleic acid. In this manner the nucleic acid becomes bound to the substrate. Any unbound nucleic acid is

38

preferably washed from the substrate before adding nanoparticle-oligonucleotide conjugates.

Next, the nucleic acid bound to the substrate is contacted with a first type of nanoparticles having

5   oligonucleotides attached thereto. The oligonucleotides have a sequence complementary to a second portion of the sequence of the nucleic acid, and the contacting takes place under conditions effective to allow hybridization of the oligonucleotides on the nanoparticles with the nucleic acid.

10   In this manner the first type of nanoparticles become bound to the substrate. After the nanoparticle-oligonucleotide conjugates are bound to the substrate, the substrate is washed to remove any unbound nanoparticle-oligonucleotide conjugates and nucleic acid.

15   The oligonucleotides on the first type of nanoparticles may all have the same sequence or may have different sequences that hybridize with different portions of the nucleic acid to be detected. When oligonucleotides having different sequences are used, each nanoparticle may have all

20   of the different oligonucleotides attached to it or, preferably, the different oligonucleotides are attached to different nanoparticles. Figure 17 illustrates the use of nanoparticle-oligonucleotide conjugates designed to hybridize to multiple portions of a nucleic acid.

25   Finally, the first type of nanoparticle-oligonucleotide conjugates bound to the substrate is contacted with a second type of nanoparticles having oligonucleotides attached thereto. These oligonucleotides have a sequence complementary to at least a portion of the sequence(s) of

39

the oligonucleotides attached to the first type of
nanoparticles, and the contacting takes place under
conditions effective to allow hybridization of the
oligonucleotides on the first type of nanoparticles with

5   those on the second type of nanoparticles. After the
nanoparticles are bound, the substrate is preferably washed
to remove any unbound nanoparticle-oligonucleotide
conjugates.

The combination of hybridizations produces a detectable

10   change. The detectable changes are the same as those
described above, except that the multiple hybridizations
result in an amplification of the detectable change. In
particular, since each of the first type of nanoparticles
has multiple oligonucleotides (having the same or different

15   sequences) attached to it, each of the first type of
nanoparticle-oligonucleotide conjugates can hybridize to a
plurality of the second type of nanoparticle-oligonucleotide
conjugates. Also, the first type of nanoparticle-
oligonucleotide conjugates may be hybridized to more than

20   one portion of the nucleic acid to be detected. The
amplification provided by the multiple hybridizations may
make the change detectable for the first time or may
increase the magnitude of the detectable change. This
amplification increases the sensitivity of the assay,

25   allowing for detection of small amounts of nucleic acid.

If desired, additional layers of nanoparticles can be
built up by successive additions of the first and second
types of nanoparticle-oligonucleotide conjugates. In this
way, the number of nanoparticles immobilized per molecule of

40

target nucleic acid can be further increased with a corresponding increase in intensity of the signal.

Also, instead of using first and second types of nanoparticle-oligonucleotide conjugates designed to hybridize to each other directly, nanoparticles bearing oligonucleotides that would serve to bind the nanoparticles together as a consequence of hybridization with binding oligoncleotides could be used.

Methods of making the nanoparticles and the oligonucleotides and of attaching the oligonucleotides to the nanoparticles are described above. The hybridization conditions are well known in the art and can be readily optimized for the particular system employed (see above).

An example of this method of detecting nucleic acid (analyte DNA) is illustrated in Figure 13A. The combination of hybridizations produces dark areas where nanoparticle aggregates are linked to the substrate by analyte DNA. These dark areas may be readily observed with the naked eye using ambient light, preferably viewing the substrate against a white background. As can be readily seen from Figure 13A, this method provides a means of amplifying a detectable change.

In another embodiment, nanoparticles are attached to the substrate. Nanoparticles can be attached to substrates as described in, *e.g.*, Grabar et al., *Analyt. Chem.*, **67**, 73-743 (1995); Bethell et al., *J. Electroanal. Chem.*, **409**, 137 (1996); Bar et al., *Langmuir*, **12**, 1172 (1996); Colvin et al., *J. Am. Chem. Soc.*, **114**, 5221 (1992).

After the nanoparticles are attached to the substrate, oligonucleotides are attached to the nanoparticles. This may be accomplished in the same manner described above for the attachment of oligonucleotides to nanoparticles in

5   solution. The oligonucleotides attached to the nanoparticles have a sequence complementary to a first portion of the sequence of a nucleic acid.

The substrate is contacted with the nucleic acid under conditions effective to allow hybridization of the

10   oligonucleotides on the nanoparticles with the nucleic acid. In this manner the nucleic acid becomes bound to the substrate. Unbound nucleic acid is preferably washed from the substrate prior to adding further nanoparticle-oligonucleotide conjugates.

15   Then, a second type of nanoparticles having oligonucleotides attached thereto is provided. These oligonucleotides have a sequence complementary to a second portion of the sequence of the nucleic acid, and the nucleic acid bound to the substrate is contacted with the second

20   type of nanoparticle-oligonucleotide conjugates under conditions effective to allow hybridization of the oligonucleotides on the second type of nanoparticle-oligonucleotide conjugates with the nucleic acid. In this manner, the second type of nanoparticle-oligonucleotide

25   conjugates becomes bound to the substrate. After the nanoparticles are bound, any unbound nanoparticle-oligonucleotide conjugates and nucleic acid are washed from the substrate. A change (e.g., color change) may be detectable at this point.

42

The oligonucleotides on the second type of nanoparticles may all have the same sequence or may have different sequences that hybridize with different portions of the nucleic acid to be detected. When oligonucleotides
5 having different sequences are used, each nanoparticle may have all of the different oligonucleotides attached to it or, preferably, the different oligonucleotides may be attached to different nanoparticles. See Figure 17.

Next, a binding oligonucleotide having a selected
10 sequence having at least two portions, the first portion being complementary to at least a portion of the sequence of the oligonucleotides on the second type of nanoparticles, is contacted with the second type of nanoparticle-oligonucleotide conjugates bound to the substrate under
15 conditions effective to allow hybridization of the binding oligonucleotide to the oligonucleotides on the nanoparticles. In this manner, the binding oligonucleotide becomes bound to the substrate. After the binding oligonucleotides are bound, unbound binding oligonucleotides
20 are washed from the substrate.

Finally, a third type of nanoparticles having oligonucleotides attached thereto is provided. The oligonucleotides have a sequence complementary to the sequence of a second portion of the binding oligonucleotide.
25 The nanoparticle-oligonucleotide conjugates are contacted with the binding oligonucleotide bound to the substrate under conditions effective to allow hybridization of the binding oligonucleotide to the oligonucleotides on the nanoparticles. After the nanoparticles are bound, unbound

43

nanoparticle-oligonucleotide conjugates are washed from the substrate.

The combination of hybridizations produces a detectable change. The detectable changes are the same as those
5   described above, except that the multiple hybridizations result in an amplification of the detectable change. In particular, since each of the second type of nanoparticles has multiple oligonucleotides (having the same or different sequences) attached to it, each of the second type of
10   nanoparticle-oligonucleotide conjugates can hybridize to a plurality of the third type of nanoparticle-oligonucleotide conjugates (through the binding oligonucleotide). Also, the second type of nanoparticle-oligonucleotide conjugates may be hybridized to more than one portion of the nucleic acid
15   to be detected. The amplification provided by the multiple hybridizations may make the change detectable for the first time or may increase the magnitude of the detectable change. The amplification increases the sensitivity of the assay, allowing for detection of small amounts of nucleic acid.
20   If desired, additional layers of nanoparticles can be built up by successive additions of the binding oligonucleotides and second and third types of nanoparticle-oligonucleotide conjugates. In this way, the nanoparticles immobilized per molecule of target nucleic acid can be
25   further increased with a corresponding increase in intensity of the signal.

Also, the use of the binding oligonucleotide can be eliminated, and the second and third types of nanoparticle-

44

oligonucleotide conjugates can be designed so that they hybridize directly to each other.

Methods of making the nanoparticles and the oligonucleotides and of attaching the oligonucleotides to the nanoparticles are described above. The hybridization conditions are well known in the art and can be readily optimized for the particular system employed (see above).

An example of this method of detecting nucleic acid (analyte DNA) is illustrated in Figure 13B. The combination of hybridizations produces dark areas where nanoparticle aggregates are linked to the substrate by analyte DNA. These dark areas may be readily observed with the naked eye as described above. As can be seen from Figure 13B, this embodiment of the method of the invention provides another means of amplifying the detectable change.

Another amplification scheme employs liposomes. In this scheme, oligonucleotides are attached to a substrate. Suitable substrates are those described above, and the oligonucleotides can be attached to the substrates as described above. For instance, where the substrate is glass, this can be accomplished by condensing the oligonucleotides through phosphoryl or carboxylic acid groups to aminoalkyl groups on the substrate surface (for related chemistry see Grabar et al., *Anal. Chem.*, 67, 735-743 (1995)).

The oligonucleotides attached to the substrate have a sequence complementary to a first portion of the sequence of the nucleic acid to be detected. The nucleic acid is contacted with the substrate under conditions effective to

45

allow hybridization of the oligonucleotides on the substrate with the nucleic acid. In this manner the nucleic acid becomes bound to the substrate. Any unbound nucleic acid is preferably washed from the substrate before adding

5   additional components of the system.

Next, the nucleic acid bound to the substrate is contacted with liposomes having oligonucleotides attached thereto. The oligonucleotides have a sequence complementary to a second portion of the sequence of the nucleic acid, and

10   the contacting takes place under conditions effective to allow hybridization of the oligonucleotides on the liposomes with the nucleic acid. In this manner the liposomes become bound to the substrate. After the liposomes are bound to the substrate, the substrate is washed to remove any unbound

15   liposomes and nucleic acid.

The oligonucleotides on the liposomes may all have the same sequence or may have different sequences that hybridize with different portions of the nucleic acid to be detected. When oligonucleotides having different sequences are used,

20   each liposome may have all of the different oligonucleotides attached to it or the different oligonucleotides may be attached to different liposomes.

To prepare oligonucleotide-liposome conjugates, the oligonucleotides are linked to a hydrophobic group, such as

25   cholesteryl (see Letsinger et al., *J. Am. Chem. Soc.*, **115**, 7535-7536 (1993)), and the hydrophobic-oligonucleotide conjugates are mixed with a solution of liposomes to form liposomes with hydrophobic-oligonucleotide conjugates anchored in the membrane (see Zhang et al., *Tetrahedron*

46

Lett., **37**, 6243-6246 (1996)). The loading of hydrophobic-oligonucleotide conjugates on the surface of the liposomes can be controlled by controlling the ratio of hydrophobic-oligonucleotide conjugates to liposomes in the mixture. It

5   has been observed that liposomes bearing oligonucleotides attached by hydrophobic interaction of pendent cholesteryl groups are effective in targeting polynucleotides immobilized on a nitrocellulose membrane (*Id.*). Fluorescein groups anchored in the membrane of the liposome were used as

10   the reporter group. They served effectively, but sensitivity was limited by the fact that the signal from fluorescein in regions of high local concentration (*e.g.*, on the liposome surface) is weakened by self quenching.

The liposomes are made by methods well known in the

15   art. See Zhang et al., *Tetrahedron Lett.*, **37**, 6243 (1996). The liposomes will generally be about 5-50 times larger in size (diameter) than the nanoparticles used in subsequent steps. For instance, for nanoparticles about 13 nm in diameter, liposomes about 100 nm in diameter are preferably

20   used.

The liposomes bound to the substrate are contacted with a first type of nanoparticles having at least a first type of oligonucleotides attached thereto. The first type of oligonucleotides have a hydrophobic group attached to the

25   end not attached to the nanoparticles, and the contacting takes place under conditions effective to allow attachment of the oligonucleotides on the nanoparticles to the liposomes as a result of hydrophobic interactions. A detectable change may be observable at this point.

47

The method may further comprise contacting the first type of nanoparticle-oligonucleotide conjugates bound to the liposomes with a second type of nanoparticles having oligonucleotides attached thereto. The first type of nanoparticles have a second type of oligonucleotides attached thereto which have a sequence complementary to at least a portion of the sequence of the oligonucleotides on the second type of nanoparticles, and the oligonucleotides on the second type of nanoparticles have a sequence complementary to at least a portion of the sequence of the second type of oligonucleotides on the first type of nanoparticles. The contacting takes place under conditions effective to allow hybridization of the oligonucleotides on the first and second types of nanoparticles. This hybridization will generally be performed at mild temperatures (e.g., 5°C to 60°C), so conditions (*e.g.*, 0.3-1.0 M NaCl) conducive to hybridization at room temperature are employed. Following hybridization, unbound nanoparticle-oligonucleotide conjugates are washed from the substrate.

The combination of hybridizations produces a detectable change. The detectable changes are the same as those described above, except that the multiple hybridizations result in an amplification of the detectable change. In particular, since each of the liposomes has multiple oligonucleotides (having the same or different sequences) attached to it, each of the liposomes can hybridize to a plurality of the first type of nanoparticle-oligonucleotide conjugates. Similarly, since each of the first type of

48

nanoparticles has multiple oligonucleotides attached to it, each of the first type of nanoparticle-oligonucleotide conjugates can hybridize to a plurality of the second type of nanoparticle-oligonucleotide conjugates. Also, the

5   liposomes may be hybridized to more than one portion of the nucleic acid to be detected. The amplification provided by the multiple hybridizations may make the change detectable for the first time or may increase the magnitude of the detectable change. This amplification increases the

10   sensitivity of the assay, allowing for detection of small amounts of nucleic acid.

     If desired, additional layers of nanoparticles can be built up by successive additions of the first and second types of nanoparticle-oligonucleotide conjugates. In this

15   way, the number of nanoparticles immobilized per molecule of target nucleic acid can be further increased with a corresponding increase in the intensity of the signal. Further enhancement can also be obtained by employing silver staining of gold nanoparticles (Bassell, et al., *J. Cell*

20   *Biol.*, **126**, 863-876 (1994); Braun-Howland et al., *Biotechniques*, **13**, 928-931 (1992)).

     Also, instead of using second and third types of nanoparticle-oligonucleotide conjugates designed to hybridize to each other directly, nanoparticles bearing

25   oligonucleotides that would serve to bring the nanoparticles together as a consequence of hybridization with binding oligonucleotides could be used.

     Methods of making the nanoparticles and the oligonucleotides and of attaching the oligonucleotides to

49

the nanoparticles are described above. A mixture of oligonucleotides functionalized at one end for binding to the nanoparticles and with or without a hydrophobic group at the other end can be used on the first type of

5   nanoparticles. The relative ratio of these oligonucleotides bound to the average nanoparticle will be controlled by the ratio of the concentrations of the two oligonucleotides in the mixture. The hybridization conditions are well known in the art and can be readily optimized for the particular

10   system employed (see above).

An example of this method of detecting nucleic acid is illustrated in Figure 18. The hybridization of the first type of nanoparticle-oligonucleotide conjugates to the liposomes may produce a detectable change. In the case of

15   gold nanoparticles, a pink/red color may be observed or a purple/blue color may be observed if the nanoparticles are close enough together. The hybridization of the second type of nanoparticle-oligonucleotide conjugates to the first type of nanoparticle-oligonucleotide conjugates will produce a

20   detectable change. In the case of gold nanoparticles, a purple/blue color will be observed. All of these color changes may be observed with the naked eye.

When a substrate is employed, a plurality of the initial types of nanoparticle-oligonucleotide conjugates or

25   oligonucleotides can be attached to the substrate in an array for detecting multiple portions of a target nucleic acid, for detecting multiple different nucleic acids, or both. For instance, a substrate may be provided with rows of spots, each spot containing a different type of

50

oligonucleotide or oligonucleotide-nanoparticle conjugate designed to bind to a portion of a target nucleic acid. A sample containing one or more nucleic acids is applied to each spot, and the rest of the assay is performed in one of

5 the ways described above using appropriate oligonucleotide-nanoparticle conjugates, oligonucleotide-liposome conjugates and binding oligonucleotides.

A nanoparticle-oligonucleotide conjugate which may be used in an assay for any nucleic acid is illustrated in

10 Figures 17D-E. This "universal probe" has oligonucleotides of a single sequence attached to it. These oligonucleotides can hybridize with a binding oligonucleotide which has a sequence comprising at least two portions. The first portion is complementary to at least a portion of the

15 sequence of the oligonucleotides on the nanoparticles. The second portion is complementary to a portion of the sequence of the nucleic acid to be detected. A plurality of binding oligonucleotides having the same first portion and different second portions can be used, in which case the "universal

20 probe", after hybridization to the binding oligonucleotides, can bind to multiple portions of the nucleic acid to be detected or to different nucleic acid targets.

In a number of other embodiments of the invention, the detectable change is created by labeling the

25 oligonucleotides, the nanoparticles, or both with molecules (e.g., fluorescent molecules and dyes) that produce detectable changes upon hydridization of the oligonucleotides on the nanoparticles with the target nucleic acid. For instance, oligonucleotides attached to

51

metal and semiconductor nanoparticles can have a fluorescent molecule attached to the end not attached to the nanoparticles. Metal and semiconductor nanoparticles are known fluorescence quenchers, with the magnitude of the

5   quenching effect depending on the distance between the nanoparticles and the fluorescent molecule. In the unhybridized state, the oligonucleotides attached to the nanoparticles interact with the nanoparticles, so that significant quenching will be observed. See Figure 20A.

10   Upon hybridization to a target nucleic acid, the fluorescent molecule will become spaced away from the nanoparticles, diminishing quenching of the fluorescence. See Figure 20A. Longer oligonucleotides should give rise to larger changes in fluorescence, at least until the fluorescent groups are

15   moved far enough away from the nanoparticle surfaces so that an increase in the change is no longer observed. Useful lengths of the oligonucleotides can be determined empirically. Metallic and semiconductor nanoparticles having fluorescent-labeled oligonucleotides attached thereto

20   can be used in any of the assay formats described above, including those performed in solution or on substrates.

Methods of labeling oligonucleotides with fluorescent molecules and measuring fluorescence are well known in the art. Suitable fluorescent molecules are also well known in

25   the art and include the fluoresceins, rhodamines and Texas Red. The oligonucleotides will be attached to the nanoparticles as described above.

In yet another embodiment, two types of fluorescent-labeled oligonucleotides attached to two different particles

52

can be used. Suitable particles include polymeric particles
(such as polystyrene particles, polyvinyl particles,
acrylate and methacrylate particles), glass particles, latex
particles, Sepharose beads and others like particles well

5   known in the art. Methods of attaching oligonucleotides to
such particles are well known in the art. See Chrisey et
al., *Nucleic Acids Research*, **24**, 3031-3039 (1996) (glass)
and Charreyre et al., *Langmuir*, **13**, 3103-3110 (1997), Fahy
et al., *Nucleic Acids Research*, **21**, 1819-1826 (1993),

10   Elaissari et al., *J. Colloid Interface Sci.*, **202**, 251-260
(1998), Kolarova et al., *Biotechniques*, **20**, 196-198 (1996)
and Wolf et al., *Nucleic Acids Research*, **15**, 2911-2926
(1987) (polymer/latex). In particular, a wide variety of
functional groups are available on the particles or can be

15   incorporated into such particles. Functional groups include
carboxylic acids, aldehydes, amino groups, cyano groups,
ethylene groups, hydroxyl groups, mercapto groups, and the
like. Nanoparticles, including metallic and semiconductor
nanoparticles, can also be used.

20   The two fluorophores are designated **d** and **a** for donor
and acceptor. A variety of fluorescent molecules useful in
such combinations are well known in the art and are
available from, *e.g.*, Molecular Probes. An attractive
combination is fluorescein as the donor and Texas Red as

25   acceptor. The two types of nanoparticle-oligonucleotide
conjugates with **d** and **a** attached are mixed with the target
nucleic acid, and fluorescence measured in a fluorimeter.
The mixture will be excited with light of the wavelength
that excites **d**, and the mixture will be monitored for

53

fluorescence from **a**. Upon hybridization, **d** and **a** will be brought in proximity (see Figure 20B). In the case of non-metallic, non-semiconductor particles, hybridization will be shown by a shift in fluorescence from that for **d** to that for

5   **a** or by the appearance of fluorescence for **a** in addition to that for **d**. In the absence of hybridization, the flurophores will be too far apart for energy transfer to be significant, and only the fluorescence of **d** will be observed. In the case of metallic and semiconductor

10   nanoparticles, lack of hybridization will be shown by a lack of fluorescence due to **d** or **a** because of quenching (see above). Hybridization will be shown by an increase in fluorescence due to **a**.

As will be appreciated, the above described particles
15   and nanoparticles having oligonucleotides labeled with acceptor and donor fluorescent molecules attached can be be used in the assay formats described above, including those performed in solution and on substrates. For solution formats, the oligonucleotide sequences are preferably chosen
20   so that they bind to the target nucleic acid as illustrated in Figures 15A-G. In the formats shown in Figure 13A-B and 18, the binding oligonucleotides may be used to bring the acceptor and donor fluorescent molecules on the two nanoparticles in proximity. Also, in the format illustrated
25   in Figure 13A, the oligonucleotides attached the substrate may be labeled with **d**. Further, other labels besides fluorescent molecules can be used, such as chemiluminescent molecules, which will give a detectable signal or a change in detectable signal upon hybridization.

Another embodiment of the detection method of the
invention is a very sensitive system that utilizes detection
of changes in fluorescence and color (illustrated in Figure
21). This system employs latex microspheres to which are
5   attached oligonucleotides labeled with a fluorescent
molecule and gold nanoparticles to which are attached
oligonucleotides. The oligonucleotide-nanoparticle
conjugates can be prepared as described above. Methods of
attaching oligonucleotides to latex microspheres are well
10   known (see, e.g., Charreyre et al., *Langmuir*, **13**:3103-3110
(1997); Elaissari et al., *J. Colloid Interface Sci.*,
202:251-260 (1998)), as are methods of labeling
oligonucleotides with fluorescent molecules (see above).
The oligonucleotides on the latex microspheres and the
15   oligonucleotides on the gold nanoparticles have sequences
capable of hybridizing with different portions of the
sequence of a target nucleic acid, but not with each other.
When a target nucleic acid comprising sequences
complementary to the sequences of the oligonucleotides on
20   the latex microspheres and gold nanoparticles is contacted
with the two probes, a network structure is formed (see
Figure 21). Due to the quenching properties of the gold
nanoparticles, the fluorescence of the oligonucleotides
attached to the latex microspheres is quenched while part of
25   this network. Indeed, one gold nanoparticle can quench many
fluorophore molecules since gold nanoparticles have very
large absorbption coefficients. Thus, the fluorescence of a
solution containing nucleic acid and the two particles can
be monitored to detect the results, with a reduction in, or

elimination of, fluorescence indicating a positive result.
Preferably, however, the results of the assay are detected
by placing a droplet of the solution onto a microporous
material (see Figure 21). The microporous material should

5   be transparent or a color (e.g., white) which allows for
detection of the pink/red color of the gold nanoparticles.
The microporous material should also have a pore size
sufficiently large to allow the gold nanoparticles to pass
through the pores and sufficiently small to retain the latex

10   microspheres on the surface of the microporous material when
the microporous material is washed. Thus, when using such a
microporous material, the size (diameter) of the latex
microspheres must be larger than the size (diameter) of the
gold nanoparticles. The microporous material must also be

15   inert to biological media. Many suitable microporous
materials are known in the art and include various filters
and membranes, such as modified polyvinylidene fluoride
(PVDF, such as Durapore™ membrane filters purchased from
Millipore Corp.) and pure cellulose acetate (such as

20   AcetatePlus™ membrane filters purchased from Micron
Separations Inc.). Such a microporous material retains the
network composed of target nucleic acid and the two probes,
and a positive result (presence of the target nucleic acid)
is evidenced by a red/pink color (due to the presence of the

25   gold nanoparticles) and a lack of fluorescence (due to
quenching of fluorescence by the gold nanoparticles) (see
Figure 21). A negative result (no target nucleic acid
present) is evidenced by a white color and fluorescence,
because the gold nanoparticles would pass through the pores

of the microporous material when it is washed (so no quenching of the fluorescence would occur), and the white latex microspheres would be trapped on top of it (see Figure 21). In addition, in the case of a positive result, changes

5   in fluorescence and color can be observed as a function of temperature. For instance, as the temperature is raised, fluorescence will be observed once the dehybridization temperature has been reached. Therefore, by looking at color or fluorescence as a function of temperature,

10 information can be obtained about the degree of complementarity between the oligonucleotide probes and the target nucleic acid. As noted above, this detection method exhibits high sensitivity. As little as 3 femtomoles of single-stranded target nucleic acid 24 bases in length and

15 20 femtomoles of double-stranded target nucleic acid 24 bases in length have been detected with the naked eye. The method is also very simple to use. Fluorescence can be generated by simply illuminating the solution or microporous material with a UV lamp, and the fluorescent and

20 colorimetric signals can be monitored by the naked eye. Alternatively, for a more quantitative result, a fluorimeter can be employed in front-face mode to measure the fluorescence of the solution with a short pathlength.

The above embodiment has been described with particular

25 reference to latex microspheres and gold nanoparticles. Any other microsphere or nanoparticle, having the other properties described above and to which oligonucleotides can be attached, can be used in place of these particles. Many suitable particles and nanoparticles are described above,

along with techniques for attaching oligonucleotides to
them. In addition, microspheres and nanoparticles having
other measurable properties may be used. For instance,
polymer-modified particles and nanoparticles, where the

5   polymer can be modified to have any desirable property, such
as fluorescence, color, or electrochemical activity, can be
used. See, Watson et al., *J. Am. Chem. Soc.*, **121**, 462-463
(1999) (polymer-modified gold nanoparticles). Also,
magnetic, polymer-coated magnetic, and semiconducting

10   particles can be used. See Chan et al., *Science*, **281**, 2016
(1998); Bruchez et al., *Science*, **281**, 2013 (1998); Kolarova
et al., *Biotechniques*, **20**, 196-198 (1996).

In yet another embodiment, two probes comprising
metallic or semiconductor nanoparticles having

15   oligonucleotides labeled with fluorescent molecules attached
to them are employed (illustrated in Figure 22). The
oligonucleotide-nanoparticle conjugates can be prepared and
labeled with fluorescent molecules as described above. The
oligonucleotides on the two types of oligonucleotide-

20   nanoparticle conjugates have sequences capable of
hybridizing with different portions of the sequence of a
target nucleic acid, but not with each other. When a target
nucleic acid comprising sequences complementary to the
sequences of the oligonucleotides on the nanoparticles is

25   contacted with the two probes, a network structure is formed
(see Figure 22). Due to the quenching properties of the
metallic or semiconductor nanoparticles, the fluorescence of
the oligonucleotides attached to the nanoparticles is
quenched while part of this network. Thus, the fluorescence

58

of a solution containing nucleic acid and the two probes can
be monitored to detect the results, with a reduction in, or
elimination of, fluorescence indicating a positive result.
Preferably, however, the results of the assay are detected

5   by placing a droplet of the solution onto a microporous
material (see Figure 22). The microporous material should
have a pore size sufficiently large to allow the
nanoparticles to pass through the pores and sufficiently
small to retain the network on the surface of the

10   microporous material when the microporous material is washed
(see Figure 22). Many suitable microporous materials are
known in the art and include those described above. Such a
microporous material retains the network composed of target
nucleic acid and the two probes, and a positive result

15   (presence of the target nucleic acid) is evidenced by a lack
of fluorescence (due to quenching of fluorescence by the
metallic or semiconductor nanoparticles) (see Figure 22). A
negative result (no target nucleic acid present) is
evidenced by fluorescence because the nanoparticles would

20   pass through the pores of the microporous material when it
is washed (so no quenching of the fluorescence would occur)
(see Figure 22). There is low background fluorescence
because unbound probes are washed away from the detection
area. In addition, in the case of a positive result,

25   changes in fluorescence can be observed as a function of
temperature. For instance, as the temperature is raised,
fluorescence will be observed once the dehybridization
temperature has been reached. Therefore, by looking at
fluorescence as a function of temperature, information can

be obtained about the degree of complementarity between the oligonucleotide probes and the target nucleic acid. Fluorescence can be generated by simply illuminating the solution or microporous material with a UV lamp, and the

5   fluorescent signal can be monitored by the naked eye. Alternatively, for a more quantitative result, a fluorimeter can be employed in front-face mode to measure the fluorescence of the solution with a short path length.

In yet other embodiments, a "satellite probe" is used

10 (see Figure 24). The satellite probe comprises a central particle with one or several physical properties that can be exploited for detection in an assay for nucleic acids (e.g., intense color, fluorescence quenching ability, magnetism). Suitable particles include the nanoparticles and other

15 particles described above. The particle has oligonucleotides (all having the same sequence) attached to it (see Figure 24). Methods of attaching oligonucleotides to the particles are described above. These oligonucleotides comprise at least a first portion and a

20 second portion, both of which are complementary to portions of the sequence of a target nucleic acid (see Figure 24). The satellite probe also comprises probe oligonucleotides. Each probe oligonucleotide has at least a first portion and a second portion (see Figure 24). The sequence of the first

25 portion of the probe oligonucleotides is complementary to the first portion of the sequence of the oligonucleotides immobilized on the central particle (see Figure 24). Consequently, when the central particle and the probe oligonucleotides are brought into contact, the

60

oligonucleotides on the particle hybridize with the probe
oligonucleotides to form the satellite probe (see Figure
24). Both the first and second portions of the probe
oligonucleotides are complementary to portions of the

5   sequence of the target nucleic acid (see Figure 24). Each
probe oligonucleotide is labeled with a reporter molecule
(see Figure 24), as further described below. The amount of
hybridization overlap between the probe oligonucleotides and
the target (length of the portion hybridized) is as large

10   as, or greater than, the hybridization overlap between the
probe oligonucleotides and the oligonucleotides attached to
the particle (see Figure 24). Therefore, temperature
cycling resulting in dehybridization and rehybridization
would favor moving the probe oligonucleotides from the

15   central particle to the target. Then, the particles are
separated from the probe oligonucleotides hybridized to the
target, and the reporter molecule is detected.

     The satellite probe can be used in a variety of
detection strategies. For example, if the central particle

20   has a magnetic core and is covered with a material capable
of quenching the fluorescence of fluorophores attached to
the probe oligonucleotides that surround it, this system can
be used in an *in situ* fluorometric detection scheme for
nucleic acids. Functionalized polymer-coated magnetic

25   particles (Fe_3O_4) are available from several commercial
sources including Dynal (Dynabeads™) and Bangs Laboratories
(Estapor™), and silica-coated magnetic Fe_3O_4 nanoparticles
could be modified (Liu et al., *Chem. Mater.*, **10**, 3936-3940
(1998))using well-developed silica surface chemistry

(Chrisey et al., *Nucleic Acids Research*, **24**, 3031-3039 (1996)) and employed as magnetic probes as well. Further, the dye molecule, 4-((4-(dimethylamino)phenyl)-azo)benzoic acid (DABCYL) has been shown to be an efficient quencher of

5   fluorescence for a wide variety of fluorphores attached to oligonucleotides (Tyagi et al., *Nature Biotech.*, **16**, 49-53 (1998). The commercially-available succinimidyl ester of DABCYL (Molecular Probes) forms extremely stable amide bonds upon reaction with primary alkylamino groups. Thus, any

10   magnetic particle or polymer-coated magnetic particle with primary alkyl amino groups could be modified with both oligonucleotides, as well as these quencher molecules. Alternatively, the DABCYL quencher could be attached directly to the surface-bound olignucleotide, instead of the

15   alkyl amino-modified surface. The statellite probe comprising the probe oligonucleotides is brought into contact with the target. The temperature is cycled so as to cause dehybridization and rehybridization, which causes the probe oligonucleotides to move from the central particle to

20   the target. Detection is accomplished by applying a magnetic field and removing the particles from solution and measuring the fluorescence of the probe oligonucleotides remaining in solution hybridized to the target.

This approach can be extended to a colorimetric assay

25   by using magnetic particles with a dye coating in conjunction with probe oligonucleotides labeled with a dye which has optical properties that are distinct from the dye on the magnetic nanoparticles or perturb those of the dye on the magnetic nanoparticles. When the particles and the

62

probe oligonucleotides are in solution together, the
solution will exhibit one color which derives from a
combination of the two dyes. However, in the presence of a
target nucleic acid and with temperature cycling, the probe

5   oligonucleotides will move from the satellite probe to the
target. Once this has happened, application of a magnetic
field will remove the magnetic, dye-coated particles from
solution leaving behind probe oligonucleotides labeled with
a single dye hybridized to the target. The system can be

10   followed with a colorimeter or the naked eye, depending upon
target levels and color intensities.

      This approach also can be further extended to an
electrochemical assay by using an oligonucleotide-magnetic
particle conjugate in conjunction with a probe

15   oligonucleotide having attached a redox-active molecule.
Any modifiable redox-active species can be used, such as the
well-studied redox-active ferrocene derivative. A ferrocene
derivatized phosphoramidite can be attached to
oligonucleotides directly using standard phosphoramidite

20   chemistry. Mucic et al., *Chem. Commun.*, 555 (1996);
Eckstein, ed., in *Oligonucleotides and Analogues*, 1st ed.,
Oxford University, New York, NY (1991). The
ferrocenylphosphoramidite is prepared in a two-step
synthesis from 6-bromohexylferrocene. In a typical

25   preparation, 6-bromohexylferrocene is stirred in an aqueous
HMPA solution at 120°C for 6 hours to from 6-
hydroxyhexylferrocene. After purification, the 6-
hydroxyhexylferrocene is added to a THF solution of N,N-
diisopropylethylamine and beta-cyanoethyl-N,N-

63

diisopropylchlorophosphoramide to form the ferrocenylphosphoramidite. Oligonucleotide-modified polymer-coated gold nanoparticles, where the polymer contains electrochemically-active ferrocene molecules, could

5 also be utilized. Watson et al., *J. Am. Chem. Soc.*, **121**, 462-463 (1999). A copolymer of amino reactive sites (*e.g.*, anhydrides) could be incorporated into the polymer for reaction with amino-modified oligonucleotides. Moller et al., *Bioconjugate Chem.*, **6**, 174-178 (1995). In the presence

10 of target and with temperature cycling, the redox-active probe oligonucleotides will move from the satellite probe to the target. Once this has happened, application of the magnetic field will remove the magnetic particles from solution leaving behind the redox-active probe

15 oligonucleotides hybridized with the target nucleic acid. The amount of target then can be determined by cyclic voltammetry or any electrochemical technique that can interrogate the redox-active molecule.

The invention also provides kits for detecting nucleic

20 acids. In one embodiment, the kit comprises at least one container, the container holding at least two types of nanoparticles having oligonucleotides attached thereto. The oligonucleotides on the first type of nanoparticles have a sequence complementary to the sequence of a first portion of

25 a nucleic acid. The oligonucleotides on the second type of nanoparticles have a sequence complementary to the sequence of a second portion of the nucleic acid. The container may further comprise filler oligonucleotides having a sequence complementary to a third portion of the nucleic acid, the

third portion being located between the first and second portions. The filler oligonucleotide may also be provided in a separate container.

In a second embodiment, the kit comprises at least two

5   containers. The first container holds nanoparticles having oligonucleotides attached thereto which have a sequence complementary to the sequence of a first portion of a nucleic acid. The second container holds nanoparticles having oligonucleotides attached thereto which have a

10   sequence complementary to the sequence of a second portion of the nucleic acid. The kit may further comprise a third container holding a filler oligonucleotide having a sequence complementary to a third portion of the nucleic acid, the third portion being located between the first and second

15   portions.

In another alternative embodiment, the kits can have the oligonucleotides and nanoparticles in separate containers, and the oligonucleotides would have to be attached to the nanoparticles prior to performing an assay

20   to detect a nucleic acid. The oligonucleotides and/or the nanoparticles may be functionalized so that the oligonucleotides can be attached to the nanoparticles. Alternatively, the oligonucleotides and/or nanoparticles may be provided in the kit without functional groups, in which

25   case they must be functionalized prior to performing the assay.

In another embodiment, the kit comprises at least one container. The container holds metallic or semiconductor nanoparticles having oligonucleotides attached thereto. The

65

oligonucleotides have a sequence complementary to a portion of a nucleic acid and have fluorescent molecules attached to the ends of the oligonucleotides not attached to the nanoparticles.

5   In yet another embodiment, the kit comprises a substrate, the substrate having attached thereto nanoparticles. The nanoparticles have oligonucleotides attached thereto which have a sequence complementary to the sequence of a first portion of a nucleic acid. The kit also

10   includes a first container holding nanoparticles having oligonucleotides attached thereto which have a sequence complementary to the sequence of a second portion of the nucleic acid. The oligonucleotides may have the same or different sequences, but each of the oligonucleotides has a

15   sequence complementary to a portion of the nucleic acid. The kit further includes a second container holding a binding oligonucleotide having a selected sequence having at least two portions, the first portion being complementary to at least a portion of the sequence of the oligonucleotides

20   on the nanoparticles in the first container. The kit also includes a third container holding nanoparticles having oligonucleotides attached thereto, the oligonucleotides having a sequence complementary to the sequence of a second portion of the binding oligonucleotide.

25   In another embodiment, the kit comprises a substrate having oligonucleotides attached thereto which have a sequence complementary to the sequence of a first portion of a nucleic acid. The kit also includes a first container holding nanoparticles having oligonucleotides attached

66

thereto which have a sequence complementary to the sequence
of a second portion of the nucleic acid. The
oligonucleotides may have the same or different sequences,
but each of the oligonucleotides has a sequence

5   complementary to a portion of the nucleic acid. The kit
further includes a second container holding nanoparticles
having oligonucleotides attached thereto which have a
sequence complementary to at least a portion of the
oligonucleotides attached to the nanoparticles in the first

10   container.

In yet another embodiment, the kits can have the
substrate, oligonucleotides and nanoparticles in separate
containers. The substrate, oligonucleotides, and
nanoparticles would have to be appropriately attached to

15   each other prior to performing an assay to detect a nucleic
acid. The substrate, oligonucleotides and/or the
nanoparticles may be functionalized to expedite this
attachment. Alternatively, the substrate, oligonucleotides
and/or nanoparticles may be provided in the kit without

20   functional groups, in which case they must be functionalized
prior to performing the assay.

In a further embodiment, the kit comprises a substrate
having oligonucleotides attached thereto which have a
sequence complementary to the sequence of a first portion of

25   a nucleic acid. The kit also includes a first container
holding liposomes having oligonucleotides attached thereto
which have a sequence complementary to the sequence of a
second portion of the nucleic acid and a second container
holding nanoparticles having at least a first type of

oligonucleotides attached thereto, the first type of
oligonucleotides having a cholesteryl group attached to the
end not attached to the nanoparticles so that the
nanoparticles can attach to the liposomes by hydrophobic
5   interactions. The kit may further comprise a third
container holding a second type of nanoparticles having
oligonucleotides attached thereto, the oligonucleotides
having a sequence complementary to at least a portion of the
sequence of a second type of oligonucleotides attached to
10   the first type of nanoparticles. The second type of
oligonucleotides attached to the first type of nanoparticles
having a sequence complementary to the sequence of the
oligonucleotides on the second type of nanoparticles.

In a further embodiment, the kit may comprise a first
15   container holding nanoparticles having oligonucleotides
attached thereto. The kit also includes one or more
additional containers, each container holding a binding
oligonucleotide. Each binding oligonucleotide has a first
portion which has a sequence complementary to at least a
20   portion of the sequence of oligonucleotides on the
nanoparticles, and a second portion which has a sequence
complementary to the sequence of a portion of a nucleic acid
to be detected. The sequences of the second portions of the
binding oligonucleotides may be different as long as each
25   sequence is complementary to a portion of the sequence of
the nucleic acid to be detected.

In another embodiment, the kit comprises a container
holding one type of nanoparticles having oligonucleotides
attached thereto and one or more types of binding

68

oligonucleotides. Each of the types of binding
oligonucleotides has a sequence comprising at least two
portions. The first portion is complementary to the
sequence of the oligonucleotides on the nanoparticles,

5   whereby the binding oligonucleotides are hybridized to the
oligonucleotides on the nanoparticles in the container(s).
The second portion is complementary to the sequence of a
portion of the nucleic acid.

        In another embodiment, kits may comprise one or two

10   containers holding two types of particles. The first type
of particles having oligonucleotides attached thereto which
have a sequence complementary to the sequence of a first
portion of a nucleic acid. The oligonucleotides are labeled
with an energy donor on the ends not attached to the

15   particles. The second type of particles having
oligonucleotides attached thereto which have a sequence
complementary to the sequence of a second portion of a
nucleic acid. The oligonucleotides are labeled with an
energy acceptor on the ends not attached to the particles.

20   The energy donors and acceptors may be fluorescent
molecules.

        In a further embodiment, the kit comprises a first
container holding a type of latex microspheres having
oligonucleotides attached thereto. The oligonucleotides

25   have a sequence complementary to a first portion of the
sequence of a nucleic acid and are labeled with a
fluorescent molecule. The kit also comprises a second
container holding a type of gold nanoparticles having
oligonucleotides attached thereto. These oligonucleotides

69

have a sequence complementary to a second portion of the sequence of the nucleic acid.

In another embodiment, the kit comprises a first container holding a first type of metallic or semiconductor
5   nanoparticles having oligonucleotides attached thereto. The oligonucleotides have a sequence complementary to a first portion of the sequence of a nucleic acid and are labeled with a fluorescent molecule. The kit also comprises a second container holding a second type of metallic or
10 semiconductor nanoparticles having oligonucleotides attached thereto. These oligonucleotides have a sequence complementary to a second portion of the sequence of a nucleic acid and are labeled with a fluorescent molecule.

In a further embodiment, the kit comprises a container
15 holding a satellite probe. The satellite probe comprises a particle having attached thereto oligonucleotides. The oligonucleotides have a first portion and a second portion, both portions having sequences complementary to portions of the sequence of a nucleic acid. The satellite probe also
20 comprises probe oligonucleotides hybridized to the oligonucleotides attached to the nanoparticles. The probe oligonucleotides have a first portion and a second portion. The first portion has a sequence complementary to the sequence of the first portion of the oligonucleotides
25 attached to the particles, and both portions have sequences complementary to portions of the sequence of the nucleic acid. The probe oligonucleotides also have a reporter molecule attached to one end.

70

The kits may also contain other reagents and items useful for detecting nucleic acid. The reagents may include PCR reagents, hybridization reagents, buffers, etc. Other items which may be provided as part of the kit include a

5 solid surface (for visualizing hybridization) such as a TLC silica plate, microporous materials, syringes, pipettes, cuvettes, containers, and a thermocycler (for controlling hybridization and de-hybridization temperatures). Reagents for functionalizing the nucleotides or nanoparticles may

10 also be included in the kit.

The precipitation of aggregated nanoparticles provides a means of separating a selected nucleic acid from other nucleic acids. This separation may be used as a step in the purification of the nucleic acid. Hybridization conditions

15 are those described above for detecting a nucleic acid. If the temperature is below the Tm (the temperature at which one-half of an oligonuceotide is bound to its complementary strand) for the binding of the oligonucleotides on the nanoparticles to the nucleic acid, then sufficient time is

20 needed for the aggregate to settle. The temperature of hybridization (e.g., as measured by Tm) varies with the type of salt (NaCl or $MgCl_2$) and its concentration. Salt compositions and concentrations are selected to promote hybridization of the oligonucleotides on the nanoparticles

25 to the nucleic acid at convenient working temperatures without inducing aggregation of the colloids in the absence of the nucleic acid.

The invention also provides a method of nanofabrication. The method comprises providing at least

71

one type of linking oligonucleotide having a selected

sequence. A linking oligonucleotide used for

nanofabrication may have any desired sequence and may be

single-stranded or double-stranded. It may also contain

5 chemical modifications in the base, sugar, or backbone

sections. The sequences chosen for the linking

oligonucleotides and their lengths and strandedness will

contribute to the rigidity or flexibility of the resulting

nanomaterial or nanostructure, or a portion of the

10 nanomaterial or nanostructure. The use of a single type of

linking oligonucleotide, as well as mixtures of two or more

different types of linking oligonucleotides, is

contemplated. The number of different linking

oligonucleotides used and their lengths will contribute to

15 the shapes, pore sizes and other structural features of the

resulting nanomaterials and nanostructures.

The sequence of a linking oligonucleotide will have at

least a first portion and a second portion for binding to

oligonucleotides on nanoparticles. The first, second or

20 more binding portions of the linking oligonucleotide may

have the same or different sequences.

If all of the binding portions of a linking

oligonucleotide have the same sequence, only a single type

of nanoparticle with oligonucleotides having a complementary

25 sequence attached thereto need be used to form a

nanomaterial or nanostructure. If the two or more binding

portions of a linking oligonucleotide have different

sequences, then two or more nanoparticle-oligonucleotide

conjugates must be used. *See, e.g.,* Figure 17. The

72

oligonucleotides on each of the nanoparticles will have a
sequence complementary to one of the two or more binding
portions of the sequence of the linking oligonucleotide The
number, sequence(s) and length(s) of the binding portions
5   and the distance(s), if any, between them will contribute to
the structural and physical properties of the resulting
nanomaterials and nanostructures. Of course, if the linking
oligonucleotide comprises two or more portions, the
sequences of the binding portions must be chosen so that
10   they are not complementary to each other to avoid having one
portion of the linking nucleotide bind to another portion.

The linking oligonucleotides and nanoparticle-
oligonucleotide conjugates are contacted under conditions
effective for hybridization of the oligonucleotides attached
15   to the nanoparticles with the linking oligonucleotides so
that a desired nanomaterial or nanostructure is formed
wherein the nanoparticles are held together by
oligonucleotide connectors. These hybridization conditions
are well known in the art and can be optimized for a
20   particular nanofabrication scheme (see above). Stringent
hybridization conditions are preferred.

The invention also provides another method of
nanofabrication. This method comprises providing at least
two types of nanoparticle-oligonucleotide conjugates. The
25   oligonucleotides on the first type of nanoparticles have a
sequence complementary to that of the oligonucleotides on
the second type of nanoparticles. The oligonucleotides on
the second type of nanoparticles have a sequence
complementary to that of the oligonucleotides on the first

type of nanoparticles. The nanoparticle-oligonucleotide conjugates are contacted under conditions effective to allow hybridization of the oligonucleotides on the nanoparticles to each other so that a desired nanomaterial or

5   nanostructure is formed wherein the nanoparticles are held together by oligonucleotide connectors. Again, these hybridization conditions are well-known in the art and can be optimized for a particular nanofabrication scheme.

In both nanofabrication methods of the invention, the
10 use of nanoparticles having one or more different types of oligonucleotides attached thereto is contemplated. The number of different oligonucleotides attached to a nanoparticle and the lengths and sequences of the one or more oligonucleotides will contribute to the rigidity and
15 structural features of the resulting nanomaterials and nanostructures.

Also, the size, shape and chemical composition of the nanoparticles will contribute to the properties of the resulting nanomaterials and nanostructures. These
20 properties include optical properties, optoelectronic properties, stability in various solutions, pore and channel size variation, ability to separate bioactive molecules while acting as a filter, etc. The use of mixtures of nanoparticles having different sizes, shapes and/or chemical
25 compositions, as well as the use of nanoparticles having uniform sizes, shapes and chemical composition, are contemplated.

In either fabrication method, the nanoparticles in the resulting nanomaterial or nanostructure are held together by

oligonucleotide connectors. The sequences, lengths, and
strandedness of the oligonucleotide connectors, and the
number of different oligonucleotide connectors present will
contribute to the rigidty and structural properties of the

5   nanomaterial or nanostructure. If an oligonucleotide
connector is partially double-stranded, its rigidity can be
increased by the use of a filler oligonucleotide as
described above in connection with the method of detecting
nucleic acid. The rigidity of a completely double-stranded

10   oligonucleotide connector can be increased by the use of one
or more reinforcing oligonucleotides having complementary
sequences so that they bind to the double-stranded
oligonucleotide connector to form triple-stranded
oligonucleotide connectors. The use of quadruple-stranded

15   oligonucleotide connectors based on deoxyquanosine or
deoxycytidine quartets is also contemplated.

    Several of a variety of systems for organizing
nanoparticles based on oligonucleotide hybridization are
illustrated in the figures. In a simple system (Figure 1)

20   one set of nanoparticles bears oligonucleotides with a
defined sequence and another set of nonoparticles bears
oligonucleotides with a complementary sequence. On mixing
the two sets of nanoparticle-oligonucleotide conjugates
under hybridization conditions, the two types of particles

25   are linked by double stranded oligonucleotide connectors
which serve as spacers to position the nanoparticles at
selected distances.

    An attractive system for spacing nanoparticles involves
the addition of one free linking oligonucleotide as

75

illustrated in Figure 2. The sequence of the linking
oligonucleotide will have at least a first portion and a
second portion for binding to oligonucleotides on
nanoparticles. This system is basically the same as

5   utilized in the nucleic acid detection method, except that
the length of the added linking oligonucleotide can be
selected to be equal to the combined lengths of
oligonucleotides attached to the nanoparticles. The related
system illustrated in Figure 3 provides a convenient means

10   to tailor the distance between nanoparticles without having
to change the sets of nanoparticle-oligonucleotide
conjugates employed.

A further elaboration of the scheme for creating
defined spaces between nanoparticles is illustrated in

15   Figure 4. In this case a double stranded segment of DNA or
RNA containing overhanging ends is employed as the linking
oligonucleotide. Hybridization of the single-stranded,
overhanging segments of the linking oligonucleotide with the
oligonucleotides attached to the nanoparticles affords

20   multiple double-stranded oligonucleotide cross-links between
the nanoparticles.

Stiffer nanomaterials and nanostructures, or portions
thereof, can be generated by employing triple-stranded
oligonucleotide connectors between nanoparticles. In

25   forming the triple strand, one may exploit either the
pyrimidine:purine:pyrimidine motif (Moser, H.E. and Dervan,
P.B. *Science,* **238**, 645-650 (1987) or the
purine:purine:pyrimidine motif (Pilch, D.S. et al.
Biochemistry, **30**, 6081-6087 (1991). An example of the

organization of nanoparticles by generating triple-stranded
connectors by the pyrimidine:purine:pyrimidine motif are
illustrated in Figure 10. In the system shown in Figure 10,
one set of nanoparticles is conjugated with a defined strand

5   containing pyrimidine nucleosides and the other set is
conjugated with a complementary oligonucleotide containing
purine nucleosides. Attachment of the oligonucleotides is
designed such that the nanoparticles are separated by the
double-stranded oligonucleotide formed on hybridization.

10   Then, a free pyrimidine oligonucleotide with an orientation
opposite that for the pyrimidine strand linked to the
nanoparticle is added to the system prior to, simultaneously
with, or just subsequent to mixing the nanoparticles. Since
the third strand in this system is held by Hoogsteen base

15   pairing, the triple strand is relatively unstable thermally.
Covalent bridges spanning the breadth of the duplex are
known to stabilize triple-stranded complexes (Salunke, M.,
Wu, T., Letsinger, R.L., *J. Am, Chem. Soc.* **114**, 8768-8772,
(1992). Letsinger, R.L. and Wu, T. *J. Am Chem. Soc.*, **117**,

20 .   7323-7328 (1995). Prakash, G. and Kool, *J. Am. Chem. Soc.*,
114, 3523-3527 (1992).

        For construction of nanomaterials and nanostructures,
it may be desirable in some cases to "lock" the assembly in
place by covalent cross-links after formation of the

25   nanomaterial or nanostructure by hybridization of the
oligonucleotide components. This can be accomplished by
incorporating functional groups that undergo a triggered
irreversible reaction into the oligonucleotides. An example
of a functional group for this purpose is a

stilbenedicarboxamide group. It has been demonstrated that two stilbenedicarboxamide groups aligned within hybridized oligonucleotides readily undergo cross-linking on irradiation with ultraviolet light (340 nm) (Lewis, F.D. et

5   al. (1995) *J Am. Chem. Soc.* **117**, 8785-8792).

Alternatively, one could employ the displacement of a 5'-O-tosyl group from an oligonucleotide, held at the 3'-position to a nanoparticle by a mercaptoalkly group, with a thiophosphoryl group at the 3'-end of an oligonucleotide

10   held to an nanoparticle by a mercaptoalkyl group. In the presence of an oligonucleotide that hybridizes to both oligonucleotides and, thereby, brings the thiophosphoryl group into proximity of the tosyl group, the tosyl group will be displaced by the thiophosphoryl group, generating an

15   oligonucleotide linked at the ends to two different nanoparticles. For displacement reactions of this type, see Herrlein et al., *J. Am. Chem. Soc.*, **177**, 10151-10152 (1995). The fact that thiophosphoryl oligonucleotides do not react with gold nanoparticles under the conditions employed in

20   attaching mercaptoalkyl-oligonucleotides to gold nanoparticles enables one to prepare gold nanoparticle-oligonucleotide conjugates anchored through the mercapto group to the nanoparticles and containing a terminal thiophosphoryl group free for the coupling reaction.

25   A related coupling reaction to lock the assembled nanoparticle system in place utilizes displacement of bromide from a terminal bromoacetylaminonucleoside by a terminal thiophosphoryl-oligonucleotide as described in Gryaznov and Letsinger, *J. Am. Chem. Soc.*, **115**, 3808. This

reaction proceeds much like the displacement of tosylate described above, except that the reaction is faster. Nanoparticles bearing oligonucleotides terminated with thiophosphoryl groups are prepared as described above. For

5   preparation of nanoparticles bearing oligonucleotides terminated with bromoacetylamino groups, one first prepares an oligonucleotide terminated at one end by an aminonucleoside (e.g., either 5'-amino-5'-deoxythymidine or 3'-amino-3'-deoxythymidine) and at the other end by a

10   mercaptoalkyl group. Molecules of this oligoncleotide are then anchored to the nanoparticles through the mercapto groups, and the nanoparticle-oligonucleotide conjugate is then converted the N-bromoacetylamino derivative by reaction with a bromoacetyl acylating agent.

15   A fourth coupling scheme to lock the assemblies in place utilizes oxidation of nanoparticles bearing oligonucleotides terminated by thiophosphoryl groups. Mild oxidizing agents, such as potassium triiodide, potassium ferricyanide (see Gryaznov and Letsinger, *Nucleic Acids*

20   *Research*, **21**, 1403) or oxygen, are preferred.

In addition, the properties of the nanomaterials and nanostructures can be altered by incorporating into the interconnecting oligonucleotide chains organic and inorganic functions that are held in place by covalent attachment to

25   the oligonucleotide chains. A wide variety of backbone, base and sugar modifications are well known (see for example Uhlmann, E., and Peyman, A. *Chemical Reviews*, **90**, 544-584 (1990). Also, the oligonucleotide chains could be replaced by "Peptide Nucleic Acid" chains (PNA), in which the

nucleotide bases are held by a polypeptide backbone (see Wittung, P. et al., *Nature*, **368**, 561-563 (1994).

As can be seen from the foregoing, the nanofabrication method of the invention is extremely versatile. By varying the length, sequence and strandedness of the linking oligonucleotides, the number, length, and sequence of the binding portions of the linking oligonucleotides, the length, sequence and number of the oligonucleotides attached to the nanoparticles, the size, shape and chemical composition of the nanoparticles, the number and types of different linking oligonucleotides and nanoparticles used, and the strandedness of the oligonucleotide connectors, nanomaterials and nanostructures having a wide range of structures and properties can be prepared. These structures and properties can be varied further by cross-linking of the oligonucleotide connectors, by functionalizing the oligonucleotides, by backbone, base or sugar modifications of the oligonucleotides, or by the use of peptide-nucleic acids.

The nanomaterials and nanostructures that can be made by the nanofabrication method of the invention include nanoscale mechanical devices, separation membranes, bio-filters, and biochips. It is contemplated that the nanomaterials and nanostructures of the invention can be used as chemical sensors, in computers, for drug delivery, for protein engineering, and as templates for biosynthesis/ nanostructure fabrication/directed assembly of other structures. See generally Seeman et al., *New J. Chem.*, **17**, 739 (1993) for other possible applications.

80

It is to be noted that the term "a" or "an" entity refers to one or more of that entity. For example, "a characteristic" refers to one or more characteristics or at least one characteristic. As such, the terms "a" (or "an"),

5   "one or more" and "at least one" are used interchangeably herein. It is also to be noted that the terms "comprising", "including", and "having" have been used interchangeably.

81

EXAMPLES

Example 1:   Preparation of Oligonucleotide-Modified
             Gold Nanoparticles

5   A. Preparation Of Gold Nanoparticles

Gold colloids (13 nm diameter) were prepared by reduction of HAuCl$_4$ with citrate as described in Frens, *Nature Phys. Sci.*, **241**, 20 (1973) and Grabar, *Anal. Chem.*, **67**, 735 (1995). Briefly, all glassware was cleaned in aqua regia (3 parts HCl, 1 part HNO$_3$), rinsed with Nanopure H$_2$O, then oven dried prior to use. HAuCl$_4$ and sodium citrate were purchased from Aldrich Chemical Company. Aqueous HAuCl$_4$ (1 mM, 500 mL) was brought to reflux while stirring. Then, 38.8 mM sodium citrate (50 mL) was added quickly. The solution color changed from pale yellow to burgundy, and refluxing was continued for 15 min. After cooling to room temperature, the red solution was filtered through a Micron Separations Inc. 1 micron filter. Au colloids were characterized by UV-vis spectroscopy using a Hewlett Packard 8452A diode array spectrophotometer and by Transmission Electron Microscopy (TEM) using a Hitachi 8100 transmission electron microscope. Gold particles with diameters of 13 nm will produce a visible color change when aggregated with target and probe oligonucleotide sequences in the 10-35 nucleotide range.

B. Synthesis Of Oligonucleotides

Oligonucleotides were synthesized on a 1 micromole scale using a Milligene Expedite DNA synthesizer in single

82

column mode using phosphoramidite chemistry. Eckstein, F.
(ed.) *Oligonucleotides and Analogues: A Practical Approach*
(IRL Press, Oxford, 1991). All solutions were purchased
from Milligene (DNA synthesis grade). Average coupling

5   efficiency varied from 98 to 99.8%, and the final
dimethoxytrityl (DMT) protecting group was not cleaved from
the oligonucleotides to aid in purification.

For 3'-thiol-oligonucleotides, Thiol-Modifier C3 S-S
CPG support was purchased from Glen Research and used in the

10   automated synthesizer. During normal cleavage from the
solid support (16 hr at 55° C), 0.05 M dithiothreitol (DTT)
was added to the NH$_4$OH solution to reduce the 3' disulfide
to the thiol. Before purification by reverse phase high
pressure liquid chromatography (HPLC), excess DTT was

15   removed by extraction with ethyl acetate.

For 5'-thiol oligonucleotides, 5'-Thiol-Modifier C$_6$-
phosphoramidite reagent was purchased from Glen Research,
44901 Falcon Place, Sterling, Va 20166. The
oligonucleotides were synthesized, and the final DMT

20   protecting group removed. Then, 1 ml of dry acetonitrile
was added to 100 μmole of the 5' Thiol Modifier C$_6$-
phosphoramidite. 200 μL of the amidite solution and 200 μL
of activator (fresh from synthesizer) were mixed and
introduced onto the column containing the synthesized

25   oligonucleotides still on the solid support by syringe and
pumped back and forth through the column for 10 minutes.
The support was then washed (2 x 1 mL) with dry acetonitrile
for 30 seconds. 700 μL of a 0.016 M I$_2$/H$_2$O/pyridine mixture
(oxidizer solution) was introduced into the column, and was

83

then pumped back and forth through the column with two syringes for 30 second. The support was then washed with a 1:1 mixture of CH_3CN/pyridine (2 x 1 mL) for 1 minute, followed by a final wash with dry acetonitrile (2 x 1 mL)

5   with subsequent drying of the column with a stream of nitrogen. The trityl protecting group was not removed, which aids in purification.

Reverse phase HPLC was performed with a Dionex DX500 system equipped with a Hewlett Packard ODS hypersil column

10   (4.6 x 200 mm, 5 mm particle size) using 0.03 M Et_3NH^+ OAc^- buffer (TEAA), pH 7, with a 1%/min. gradient of 95% CH_3CN/5% TEAA. The flow rate was 1 mL/ min. with UV detection at 260 nm. Preparative HPLC was used to purify the DMT-protected unmodified oligonucleotides (elution at 27 min). After

15   collection and evaporation of the buffer, the DMT was cleaved from the oligonucleotides by treatment with 80% acetic acid for 30 min at room temperature. The solution was then evaporated to near dryness, water was added, and the cleaved DMT was extracted from the aqueous

20   oligonucleotide solution using ethyl acetate. The amount of oligonucleotide was determined by absorbance at 260 nm, and final purity assessed by reverse phase HPLC (elution time 14.5 minutes).

The same protocol was used for purification of the 3'-

25   thiol-oligonucleotides, except that DTT was added after extraction of DMT to reduce the amount of disulfide formed. After six hours at 40°C, the DTT was extracted using ethyl acetate, and the oligonucleotides repurified by HPLC (elution time 15 minutes).

For purification of the 5' thiol modified
oligonucleotides, preparatory HPLC was performed under the
same conditions as for unmodified oligonucleotides. After
purification, the trityl protecting group was removed by
5   adding 150 μL of a 50 mM $AgNO_3$ solution to the dry
oligonucleotide sample. The sample turned a milky white
color as the cleavage occurred. After 20 minutes, 200 μL of
a 10 mg/ml solution of DTT was added to complex the Ag (five
minute reaction time), and the sample was centrifuged to
10   precipitate the yellow complex. The oligonucleotide
solution (<50 OD) was then transferred onto a desalting NAP-
5 column (Pharmacia Biotech, Uppsala, Sweden) for
purification (contains DNA Grade Sephadex G-25 Medium for
desalting and buffer exchange of oligonucleotides greater
15   than 10 bases). The amount of 5' thiol modified
oligonucleotide was determined by UV-vis spectroscopy by
measuring the magnitude of the absorbance at 260 nm. The
final purity was assessed by performing ion-exchange HPLC
with a Dionex Nucleopac PA-100 (4 x 250) column using a 10
20   mM NaOH solution (pH 12) with a 2%/min gradient of 10 mM
NaOH, 1M NaCl solution. Typically, two peaks resulted with
elution times of approximately 19 minutes and 25 minutes
(elution times are dependent on the length of the
oligonucleotide strand). These peaks corresponded to the
25   thiol and the disulfide oligonucleotides respectively.

C.   Attachment Of Oligonucleotides To Gold Nanoparticles
An aqueous solution of 17nM (150 μL) Au colloids,
prepared as described in part A above, was mixed with 3.75

85

μM (46 μL) 3'-thiol-TTTGCTGA, prepared as described in part B and allowed to stand for 24 hours at room temperature in 1 ml Eppendorf capped vials. A second solution of colloids was reacted with 3.75 μM (46 μL) 3'-thiol-TACCGTTG. Note

5   that these oligonucleotides are noncomplementary. Shortly before use, equal amounts of each of the two nanoparticle solutions were combined. Since the oligonucleotides are noncomplementary, no reaction took place.

The oligonucleotide-modified nanoparticles are stable

10   at elevated temperatures (80°C) and high salt concentrations (1M NaCl) for days and have not been observed to undergo particle growth. Stability in high salt concentrations is important, since such conditions are required for the hybridization reactions that form the basis of the methods

15   of detection and nanofabrication of the invention.

Example 2:   Formation Of Nanoparticle Aggregates
    A.   Preparation Of Linking Oligonucleotide
Two (nonthiolated) oligonucleotides were synthesized as

20   described in part B of Example 1. They had the following sequences:

3' ATATGCGCGA TCTCAGCAAA [SEQ ID NO:1]; and

3' GATCGCGCAT ATCAACGGTA [SEQ ID NO:2].

Mixing of these two oligonucleotides in a 1 M NaCl, 10

25   mM phosphate buffered (pH 7.0) solution, resulted in hybridization to form a duplex having a 12-base-pair overlap and two 8-base-pair sticky ends. Each of the sticky ends had a sequence which was complementary to that of one of the

oligonucleotides attached to the Au colloids prepared in part C of Example 1.

B. Formation Of Nanoparticle Aggregates

5   The linking oligonucleotides prepared in part A of this example (0.17 μM final concentration after dilution with NaCl) were added to the nanoparticle-oligonucleotide conjugates prepared in part C of Example 1 (5.1 nM final concentration after dilution with NaCl) at room temperature.

10   The solution was then diluted with aqueous NaCl (to a final concentration of 1 M) and buffered at pH 7 with 10 mM phosphate, conditions which are suitable for hybridization of the oligonucleotides. An immediate color change from red to purple was observed, and a precipitation reaction ensued.

15   See Figure 6. Over the course of several hours, the solution became clear and a pinkish-gray precipitate settled to the bottom of the reaction vessel. See Figure 6.

To verify that this process involved both the oligonucleotides and colloids, the precipitate was collected

20   and resuspended (by shaking) in 1 M aqueous NaCl buffered at pH 7. Any of the oligonucleotides not hybridized to the nanoparticles are removed in this manner. Then, a temperature/time dissociation experiment was performed by monitoring the characteristic absorbance for the hybridized

25   oligodeoxyribonucleotides (260 nm) and for the aggregated colloids which is reflective of the gold interparticle distance (700 nm). See Figure 7. Changes in absorbance at 260 and 700 nm were recorded on a Perkin-Elmer Lambda 2 UV-vis Spectrophotometer using a Peltier PTP-1 Temperature

Controlled Cell Holder while cycling the temperature at a
rate of 1°C/minute between 0°C and 80°C. DNA solutions were
approximately 1 absorbance unit(s) (OD), buffered at pH 7
using 10 mM phosphate buffer and at 1M NaCl concentration.

5   The results are shown in Figure 8A. As the temperature
was cycled between 0°C and 80°C (which is 38°C above the
dissociation temperature (T_m) for the duplex (T_m=42 °C)),
there was an excellent correlation between the optical
signatures for both the colloids and oligonucleotides. The
10   UV-vis spectrum for naked Au colloids was much less
temperature dependent, Figure 8B.

There was a substantial visible optical change when the
polymeric oligonucleotide-colloid precipitate was heated
above its melting point. The clear solution turned dark red
15   as the polymeric biomaterial de-hybridized to generate the
unlinked colloids which are soluble in the aqueous solution.
The process was reversible, as evidenced by the temperature
traces in Figure 8A.

In a control experiment, a 14-T:14-A duplex was shown
20   to be ineffective at inducing reversible Au colloid particle
aggregation. In another control experiment, a linking
oligonucleotide duplex with four base pair mismatches in the
sticky ends was found not to induce reversible particle
aggregation of oligonucleotide-modified nanoparticles
25   (prepared as described in part C of Example 1 and reacted as
described above). In a third control experiment, non-
thiolated oligonucleotides having sequences complementary to
the sticky ends of the linking oligonucleotide and reacted
with nanoparticles did not produce reversible aggregation

when the nanoparticles were combined with the linking
oligonucleotide.

Further evidence of the polymerization/assembly process
came from Transmission Electron Microscopy (TEM) studies of

5   the precipitate. TEM was performed on a Hitachi 8100
Transmission Electron Microscope. A typical sample was
prepared by dropping 100 μL of colloid solution onto a holey
carbon grid. The grid, then, was dried under vacuum and
imaged. TEM images of Au colloids linked by hybridized

10   oligonucleotides showed large assembled networks of the Au
colloids, Figure 9A. Naked Au colloids do not aggregate
under comparable conditions but rather disperse or undergo
particle growth reactions. Hayat, *Colloidal Gold:*
Principles, Methods, and Applications (Academic Press, San

15   Diego, 1991). Note that there is no evidence of colloid
particle growth in the experiments performed to date; the
hybridized colloids seem to be remarkably regular in size
with an average diameter of 13 nm.

With TEM, a superposition of layers is obtained, making

20   it difficult to assess the degree of order for three-
dimensional aggregates. However, smaller scale images of
single layer, two-dimensional aggregates provided more
evidence for the self-assembly process, Figure 9B. Close-
packed assemblies of the aggregates with uniform particle

25   separations of approximately 60 Å can be seen. This
distance is somewhat shorter than the estimated 95 Å
spacing expected for colloids connected by rigid
oligonucleotide hybrids with the sequences that were used.
However, because of the nicks in the duplex obtained after

hybridization of the oligonucleotides on the nanoparticles
to the linking oligonucleotides, these were not rigid
hybrids and were quite flexible. It should be noted that
this is a variable that can be controlled by reducing the

5   system from four overlapping strands to three (thereby
reducing the number of nicks) or by using triplexes instead
of duplexes.

    Example 3:   Preparation of Oligonucleotide-Modified
10   Gold Nanoparticles

    Gold colloids (13 nm diameter) were prepared as
described in Example 1. Thiol-oligonucleotides
$[HS(CH_2)_6OP(O)(O^-)$-oligonucleotide] were also prepared as
15 described in Example 1.

    The method of attaching thiol-oligonucleotides to gold
nanoparticles described in Example 1 was found not to
produce satisfactory results in some cases. In particular,
when long oligonucleotides were used, the oligonucleotide-
20 colloid conjugates were not stable in the presence of a
large excess of high molecular weight salmon sperm DNA used
as model for the background DNA that would normally be
present in a diagnostic system. Longer exposure of the
colloids to the thiol-oligonucleotides produced
25 oligonucleotide-colloid conjugates that were stable to
salmon sperm DNA, but the resulting conjugates failed to
hybridize satisfactorily. Further experimentation led to
the following procedure for attaching thiol-oligonucleotides
of any length to gold colloids so that the conjugates are

90

stable to high molecular weight DNA and hybridize satisfactorily.

A 1 mL solution of the gold colloids (17nM) in water was mixed with excess (3.68 μM) thiol-oligonucleotide (28

5   bases in length) in water, and the mixture was allowed to stand for 12-24 hours at room temperature. Then, 100 μL of a 0.1 M sodium hydrogen phosphate buffer, pH 7.0, and 100 μL of 1.0 M NaCl were premixed and added. After 10 minutes, 10 μL of 1% aqueous NaN_3 were added, and the mixture was

10 allowed to stand for an additional 40 hours. This "aging" step was designed to increase the surface coverage by the thiol-oligonucleotides and to displace oligonucleotide bases from the gold surface. Somewhat cleaner, better defined red spots in subsequent assays were obtained if the solution was

15 frozen in a dry-ice bath after the 40-hour incubation and then thawed at room temperature. Either way, the solution was next centrifuged at 14,000 rpm in an Eppendorf Centrifuge 5414 for about 15 minutes to give a very pale pink supernatant containing most of the oligonucleotide (as

20 indicated by the absorbance at 260 nm) along with 7-10% of the colloidal gold (as indicated by the absorbance at 520 nm), and a compact, dark, gelatinous residue at the bottom of the tube. The supernatant was removed, and the residue was resuspended in about 200 μL of buffer (10 mM phosphate,

25 0.1 M NaCl) and recentrifuged. After removal of the supernatant solution, the residue was taken up in 1.0 mL of buffer (10 mM phosphate, 0.1 M NaCl) and 10 μL of a 1% aqueous solution of NaN_3. Dissolution was assisted by drawing the solution into, and expelling it from, a pipette

91

several times. The resulting red master solution was stable

(*i.e.*, remained red and did not aggregate) on standing for

months at room temperature, on spotting on silica thin-layer

chromatography (TLC) plates (see Example 4), and on addition

5   to 2 M NaCl, 10 mM MgCl$_2$, or solutions containing high

concentrations of salmon sperm DNA.

Example 4:   Acceleration Of Hybridization of
                  Nanoparticle-Oligonucleotide Conjugates

10   The oligonucleotide-gold colloid conjugates I and II

illustrated in Figure 11 were prepared as described in

Example 3. The hybridization of these two conjugates was

extremely slow. In particular, mixing samples of conjugates

I and II in aqueous 0.1 M NaCl or in 10 mM MgCl$_2$ plus 0.1 M

15   NaCl and allowing the mixture to stand at room temperature

for a day produced little or no color change.

Two ways were found to improve hybridization. First,

faster results were obtained by freezing the mixture of

conjugates I and II (each 15 nM contained in a solution of

20   0.1 M NaCl) in a dry ice-isopropyl alcohol bath for 5

minutes and then thawing the mixture at room temperature.

The thawed solution exhibited a bluish color. When 1 μL of

the solution was spotted on a standard C-18 TLC silica plate

(Alltech Associates), a strong blue color was seen

25   immediately. The hybridization and consequent color change

caused by the freeze-thawing procedure were reversible. On

heating the hybridized solution to 80°C, the solution turned

red and produced a pink spot on a TLC plate. Subsequent

freezing and thawing returned the system to the (blue)

92

hybridized state (both solution and spot on a C-18 TLC plate). In a similar experiment in which the solution was not refrozen, the spot obtained on the C-18 TLC plate was pink.

5   A second way to obtain faster results is to warm the conjugates and target. For instance, in another experiment, oligonucleotide-gold colloid conjugates and an oligonucleotide target sequence in a 0.1 M NaCl solution were warmed rapidly to 65°C and allowed to cool to room

10   temperature over a period of 20 minutes. On spotting on a C-18 silica plate and drying, a blue spot indicative of hybridization was obtained. In contrast, incubation of the conjugates and target at room temperature for an hour in 0.1 M NaCl solution did not produce a blue color indicative of

15   hybridization. Hybridization is more rapid in 0.3 M NaCl.

Example 5:   Assays Using Nanoparticle-
             Oligonucleotide Conjugates

The oligonucleotide-gold colloid conjugates 1 and 2

20   illustrated in Figures 12A-F were prepared as described in Example 3, and the oligonucleotide target 3 illustrated in Figure 12A was prepared as described in Example 2. Mismatched and deletion targets 4, 5, 6, and 7 were purchased from the Northwestern University Biotechnology

25   Facility, Chicago, IL. These oligonucleotides were synthesized on a 40 nmol scale and purified on an reverse phase C18 cartridge (OPC). Their purity was determined by performing ion exchange HPLC.

93

Selective hybridization was achieved by heating rapidly and then cooling rapidly to the stringent temperature. For example, hybridization was carried out in 100 μL of 0.1 M NaCl plus 5 mM MgCl$_2$ containing 15 nM of each

5   oligonucleotide-colloid conjugate 1 and 2, and 3 nanomoles of target oligonucleotide 3, 4, 5, 6, or 7, heating to 74°C, cooling to the temperatures indicated in Table 1 below, and incubating the mixture at this temperature for 10 minutes. A 3 μL sample of each reaction mixture was then spotted on a

10   C-18 TLC silica plate. On drying (5 minutes), a strong blue color appeared if hybridization had taken place.

The results are presented in Table 1 below. Pink spots signify a negative test (*i.e.*, that the nanoparticles were not brought together by hybridization), and blue spots

15   signify a positive test (*i.e.*, that the nanoparticles were brought into proximity due to hybridization involving both of the oligonucleotide-colloid conjugates).

94

TABLE 1

Reactants	Results (Color)			
	45°C	50°C	60°C	74°C
1 + 2	Pink	Pink	Pink	Pink
1 + 2 + 3 (match)	Blue	Blue	Blue	Blue
1 + 2 + 4 (half complement mismatch)	Pink	Pink	Pink	Pink
1 + 2 + 5 (-6 bp)	Blue	Pink	Pink	Pink
1 + 2 + 6 (1 bp mismatch)	Blue	Blue	Pink	Pink
1 + 2 + 7 (2 bp mismatch)	Pink	Pink	Pink	Pink

As can be seen in Table 1, hybridization at 60°C gave a blue spot only for the fully-matched target 3. Hybridization at 50°C yielded blue spots with both targets 3 and 6. Hybridization at 45°C gave blue spots with targets 3, 5 and 6.

In a related series, a target containing a single mismatch T nucleotide was found to give a positive test at 58°C (blue color) and a negative test (red color) at 64°C with conjugates 1 and 2. Under the same conditions, the fully-matched target (3) gave a positive test at both temperatures, showing that the test can discriminate between a target that is fully matched and one containing a single mismatched base.

Similar results were achieved using a different hybridization method. In particular, selective hybridization was achieved by freezing, thawing and then warming rapidly to the stringent temperature. For example, hybridization was carried out in 100 μL of 0.1 M NaCl

containing 15 nM of each oligonucleotide-colloid conjugate 1 and 2, and 10 picomoles of target oligonucleotide 3, 4, 5, 6, or 7, freezing in a dry ice-isopropyl alcohol bath for 5 minutes, thawing at room temperature, then warming rapidly

5   to the temperatures indicated in Table 2 below, and incubating the mixture at this temperature for 10 minutes. A 3 μL sample of each reaction mixture was then spotted on a C-18 TLC silica plate. The results are presented in Table 2.

10

Table 2

Reactants (probes) + target	Results (color)				
	RT	35°C	40°C	54°C	64°C
(1 + 2) + 3	blue	blue	blue	blue	pink
(1 + 2)	pink	pink	pink	pink	pink
(1 + 2) + 4	pink	pink	pink	pink	pink
(1 + 2) + 5	blue	blue	pink	pink	pink
(1 + 2) + 6	blue	blue	blue	pink	pink
(1 + 2) + 7	blue	pink	pink	pink	pink

An important feature of these systems was that the

25   color change associated with the temperature change was very sharp, occurring over a temperature range of about 1°C. This indicates high cooperativity in the melting and association processes involving the colloid conjugates and enables one to easily discriminate between oligonucleotide

30   targets containing a fully-matched sequence and a single basepair mismatch.

96

The high degree of discrimination may be attributed to two features. The first is the alignment of two relatively short probe oligonucleotide segments (15 nucleotides) on the target is required for a positive signal. A mismatch in

5 either segment is more destabilizing than a mismatch in a longer probe (e.g., an oligonucleotide 30 bases long) in a comparable two-component detection system. Second, the signal at 260 nm, obtained on hybridization of the target oligonucleotides with the nanoparticle conjugates in

10 solution, is nanoparticle-based, not DNA-based. It depends on dissociation of an assembly of nanoparticles organized in a polymeric network by multiple oligonucleotide duplexes. This results in a narrowing of the temperature range that is observed for aggregate dissociation, as compared with

15 standard DNA thermal denaturation. In short, some duplexes in the crosslinked aggregates can dissociate without dispersing the nanoparticles into solution. Therefore, the temperature range for aggregate melting is very narrow (4°C) as compared with the temperature range associated with

20 melting the comparable system without nanoparticles (12°C). Even more striking and advantageous for this detection approach is the temperature range for the colorimetric response (<1°C) observe on the C18 silica plates. In principle, this three-component nanoparticle based strategy

25 will be more selective than any two-component detection system based on a single-strand probe hybridizing with target nucleic acid.

A master solution containing 1 nmol of target 3 was prepared in 100 μl of hybridization buffer (0.3 M NaCl, 10

97

mM phosphate, pH 7). One μl of this solution corresponds to 10 picomole of target oligonucleotide. Serial dilutions were performed by taking an aliquot of the master solution and diluting it to the desired concentration with

5   hybridization buffer. Table 3 shows the sensitivity obtained using 3 μl of a mixutre of probes 1 and 2 with different amounts of target 3. After performing the hybridization using freeze-thaw conditions, 3 μl aliquots of these solutions were spotted onto C-18 TLC plates to

10   determine color. In Table 3 below, pink signifies a negative test, and blue signifies a positive test.

Table 3

Amount of Target	Results
1 picomole	blue (positive)
200 femtomole	blue (positive)
100 femtomole	blue (positive)
20 femtomole	blue (positive)
10 femtomole	purplish (ambiguous)

This experiment indicates that 10 femtomoles is the lower limit of detection for this particular system.

25   Example 6:   Assays Using Nanoparticle-
                   Oligonucleotide Conjugates

DNA modified nanoparticles were adsorbed onto modified transparent substrates as shown in Figure 13B. This method involved the linking of DNA modified nanoparticles to

98

nanoparticles that were attached to a glass substrate, using DNA hybridization interactions.

Glass microscope slides were purchased from Fisher scientific. Slides were cut into approximately 5 x 15 mm pieces, using a diamond tipped scribing pen. Slides were cleaned by soaking for 20 minutes in a solution of 4:1 $H_2SO_4:H_2O_2$ at 50°C. Slides were then rinsed with copious amounts of water, then ethanol, and dried under a stream of dry nitrogen. To functionalize the slide surface with a thiol terminated silane, the slides were soaked in a degassed ethanolic 1% (by volume) mercaptopropyl-trimethoxysilane solution for 12 hours. The slides were removed from the ethanol solutions and rinsed with ethanol, then water. Nanoparticles were adsorbed onto the thiol terminated surface of the slides by soaking in solutions containing the 13 nm diameter gold nanoparticles (preparation described in Example 1). After 12 hours in the colloidal solutions, the slides were removed and rinsed with water. The resulting slides have a pink appearance due to the adsorbed nanoparticles and exhibit similar UV-vis absorbance profiles (surface plasmon absorbance peak at 520 nm) as the aqueous gold nanoparticle colloidal solutions. See Figure 14A.

DNA was attached to the nanoparticle modified surface by soaking the glass slides in 0.2 OD (1.7 μM) solution containing freshly purified 3' thiol oligonucleotide (3' thiol ATGCTCAACTCT [SEQ ID NO:33]) (synthesized as described in Examples 1 and 3). After 12 hours of soaking time, the slides were removed and rinsed with water.

99

To demonstrate the ability of an analyte DNA strand to bind nanoparticles to the modified substrate, a linking oligonucleotide was prepared. The linking oligonucleotide (prepared as described in Example 2) was 24 bp long (5'

5   TACGAGTTGAGAATCCTGAATGCG [SEQ ID NO:34]) with a sequence containing a 12 bp end that was complementary to the DNA already adsorbed onto the substrate surface (SEQ ID NO:33). The substrate was then soaked in a hybridization buffer (0.5 M NaCl, 10 mM phosphate buffer pH 7) solution containing the

10   linking oligonucleotide (0.4 OD, 1.7 μM) for 12 hours. After removal and rinsing with similar buffer, the substrate was soaked in a solution containing 13 nm diameter gold nanoparticles which had been modified with an oligonucleotide (TAGGACTTACGC 5' thiol [SEQ ID NO:35])

15   (prepared as described in Example 3) that is complementary to the unhybridized portion of the linking oligonucleotide attached to the substrate. After 12 hours of soaking, the substrate was removed and rinsed with the hybridization buffer. The substrate color had darkened to a purple color

20   and the UV-vis absorbance at 520 nm approximately doubled (Figure 14A).

To verify that the oligonucleotide modified gold nanoparticles were attached to the oligonucleotide/ nanoparticle modified surface through DNA hybridization

25   interactions with the linking oligonucleotide, a melting curve was performed. For the melting experiment, the substrate was placed in a cuvette containing 1 mL of hybridization buffer and the same apparatus used in Example 2, part B, was used. The absorbance signal due to the

100

nanoparticles (520 nm) was monitored as the temperature of the substrate was increased at a rate of 0.5°C per minute. The nanoparticle signal dramatically dropped when the temperature passed 60°C. See Figure 14B. A first

5   derivative of the signal showed a melting temperature of 62°C, which corresponds with the temperature seen for the three DNA sequences hybridized in solution without nanoparticles. See Figure 14B.

10   Example 7:   Assays Using Nanoparticle-
                                Oligonucleotide Conjugates

The detection system illustrated in Figures 15A-G was designed so that the two probes 1 and 2 align in a tail-to-tail fashion onto a complementary target 4 (see Figures 15A-

15   G). This differs from the system described in Example 5 where the two probes align contiguously on the target strand (see Figures 12A-F).

The oligonucleotide-gold nanoparticle conjugates 1 and 2 illustrated in Figures 15A-G were prepared as described in

20   Example 3, except that the nanoparticles were redispersed in hybridization buffer (0.3 M NaCl, 10 mM phosphate, pH 7). The final nanoparticle-oligonucleotide conjugate concentration was estimated to be 13 nM by measuring the reduction in intensity of the surface plasmon band at 522 nm

25   which gives rise to the red color of the nanoparticles. The oligonucleotide targets illustrated in Figures 15A-G were purchased from the Northwestern University Biotechnology Facility, Evanston, IL.

101

When 150 μL of hybridization buffer containing 13 nM oligonucleotide-nanoparticle conjugates 1 and 2 was mixed with 60 picomoles (6 μL) of target 4, the solution color immediately changed from red to purple. This color change

5 occurs as a result of the formation of large oligonucleotide-linked polymeric networks of gold nanoparticles, which leads to a red shift in the surface plasmon resonance of the nanoparticles. When the solution was allowed to stand for over 2 hours, precipitation of

10 large macroscopic aggregates was observed. A 'melting analysis' of the solution with the suspended aggregates was performed. To perform the 'melting analysis', the solution was diluted to 1 ml with hybridization buffer, and the optical signature of the aggregates at 260 nm was recorded

15 at one minute intervals as the temperature was increased from 25°C to 75°C, with a holding time of 1 minute/degree. Consistent with characterization of the aggregate as an oligonucleotide-nanoparticle polymer, a characteristic sharp transition (full width at half maximum, $FW_{1/2}$ of the first

20 derivative = 3.5°C) was observed with a "melting temperature" (T_m) of 53.5°C. This compares well with the T_m associated with the broader transition observed for oligonucleotides without nanoparticles (T_m = 54°C, $FW_{1/2}$ = ~13.5°C). The 'melting analysis' of the oligonucleotide

25 solution without nanoparticles was performed under similar conditions as the analysis with nanoparticles, except that the temperature was increased from 10-80 °C. Also, the solution was 1.04 μM in each oligonucleotide component.

102

To test the selectivity of the system, the T_m for the aggregate formed from the perfect complement 4 of probes 1 and 2 was compared with the T_m's for aggregates formed from targets that contained one base mismatches, deletions, or

5 insertions (Figures 15A-G). Significantly, all of the gold nanoparticle-oligonucleotide aggregates that contained imperfect targets exhibited significant, measurable destabilization when compared to the aggregates formed from the perfect complement, as evidenced by T_m values for the

10 various aggregates (see Figures 15A-G). The solutions containing the imperfect targets could easily be distinguished from the solution containing the perfect complement by their color when placed in a water bath held at 52.5°C. This temperature is above the T_m of the

15 mismatched polynucleotides, so only the solution with the perfect target exhibited a purple color at this temperature. A 'melting analysis' was also performed on the probe solution which contained the half-complementary target. Only a minute increase in absorbance at 260 nm was observed.

20 Next, 2 μL (20 picomoles) of each of the oligonucleotide targets (Figures 15A-G) were added to a solution containing 50 μL of each probe (13 nM) in hybridization buffer. After standing for 15 minutes at room temperature, the solutions were transferred to a

25 temperature-controlled water bath and incubated at the temperatures indicated in Table 4 below for five minutes. A 3 μl sample of each reaction mixture was then spotted on a C-18 silica plate. Two control experiments were performed to demonstrate that the alignment of both probes onto the

103

target is necessary to trigger aggregation and, therefore, a color change. The first control experiment consisted of both probes 1 and 2 without target present. The second control experiment consisted of both probes 1 and 2 with a

5 target 3 that is complementary to only one of the probe sequences (Figure 15B). The results are presented in Table 4 below. Pink spots signify a negative test, and blue spots signify a positive test.

Notably, the colorimetric transition that can be

10 detected by the naked eye occurs over less than $1°C$, thereby allowing one to easily distinguish the perfect target 4 from the targets with mismatches (5 and 6), an end deletion (7), and a one base insertion at the point in the target where the two oligonucleotide probes meet (8) (see Table 4). Note

15 that the colorimetric transition T_c is close in temperature, but not identical, to T_m. In both controls, there were no signs of particle aggregation or instability in the solutions, as evidenced by the pinkish red color which was observed at all temperatures, and they showed negative spots

20 (pink) in the plate test at all temperatures (Table 4).

The observation that the one base insertion target 8 can be differentiated from the fully complementary target 4 is truly remarkable given the complete complementarity of the insertion strand with the two probe sequences. The

25 destabilization of the aggregate formed from 8 and the nanoparticle probes appears to be due to the use of two short probes and the loss of base stacking between the two thymidine bases where the probe tails meet when hybridized to the fully complementary target. A similar effect was

104

observed when a target containing a three base pair insertion (CCC) was hybridized to the probes under comparable conditions, (T_m = 51°C). In the system described above in Example 5, targets with base insertions could not

5   be distinguished from the fully complementary target. Therefore, the system described in this example is very favorable in terms of selectivity. This system also exhibited the same sensitivity as the system described in Example 5, which is approximately 10 femtomoles without

10   amplification techniques.

The results indicate that any one base mismatch along the target strand can be detected, along with any insertions into the target strand. Importantly, the temperature range over which a color change can be detected is extremely

15   sharp, and the change occurs over a very narrow temperature range. This sharp transition indicates that there is a large degree of cooperativity in the melting process involving the large network of colloids which are linked by the target oligonucleotide strands. This leads to the

20   remarkable selectivity as shown by the data.

Table 4

Reactants (probes) + target	Results (color)					
	RT	47.6°C	50.5°C	51.4°C	52.7°C	54.5°C
(1 + 2)	pink	pink	pink	pink	pink	pink
(1 + 2) + 3	pink	pink	pink	pink	pink	pink
(1 + 2) + 4	blue	blue	blue	blue	blue	pink
(1 + 2) + 5	blue	blue	blue	pink	pink	pink
(1 + 2) + 6	blue	pink	pink	pink	pink	pink
(1 + 2) + 7	blue	blue	blue	blue	pink	pink
(1 + 2) + 8	blue	blue	pink	pink	pink	pink

Example 8:   Assays Using Nanoparticle-
              Oligonucleotide Conjugates

A set of experiments were performed involving
hybridization with 'filler' duplex oligonucleotides.

5   Nanoparticle-oligonucleotide conjugates 1 and 2 illustrated
in Figure 16A were incubated with targets of different
lengths (24, 48 and 72 bases in length) and complementary
filler oligonucleotides, as illustrated in Figures 16A-C.
Otherwise, the conditions were as described in Example 7.

10   Also, the oligonucleotides and nanoparticle-oligonucleotide
conjugates were prepared as described in Example 7.

As expected, the different reaction solutions had
markedly different optical properties after hybridization
due to the distance-dependent optical properties of the gold

15   nanoparticles. See Table 5 below. However, when these
solutions were spotted onto a C-18 TLC plate, a blue color
developed upon drying at room temperature or 80°C,
regardless of the length of the target oligonucleotide and
the distance between the gold nanoparticles. See Table 5.

20   This probably occurs because the solid support enhances
aggregation of the hybridized oligonucleotide-nanoparticle
conjugates. This demonstrates that by spotting solutions
onto the TLC plate, the distance between the gold
nanoparticles can be substantial (at least 72 bases), and

25   colorimetric detection is still possible.

107

Target Length	Results (Color)	
	Solution	TLC Plate
24 bases	Blue	Blue
48 bases	Pink	Blue
72 bases	Pink	Blue
Probes 1 + 2 only	Pink	Pink

The color changes observed in this and other examples occur when the distance between the gold nanoparticles (the interparticle distance) is approximately the same or less than the diameter of the nanoparticle. Thus, the size of the nanoparticles, the size of the oligonucleotides attached to them, and the spacing of the nanoparticles when they are hybridized to the target nucleic acid affect whether a color change will be observable when the oligonucleotide-nanoparticle conjugates hybridize with the nucleic acid targets to form aggregates. For instance, gold nanoparticles with diameters of 13 nm will produce a color change when aggregated using oligonucleotides attached to the nanoparticles designed to hybridize with target sequences 10-35 nucleotides in length. The spacing of the nanoparticles when they are hybridized to the target nucleic acid adequate to give a color change will vary with the extent of aggregation, as the results demonstrate. The results also indicate that the solid surface enhances further aggregation of already-aggregated samples, bringing the gold nanoparticles closer together.

The color change observed with gold nanoparticles is attributable to a shift and broadening of the surface

plasmon resonance of the gold. This color change is unlikely for gold nanoparticles less than about 4 nm in diameter because the lengths of the oligonucleotides necessary for specific detection of nucleic acid would

5   exceed the nanoparticle diameter.

Example 9:   Assays Using Nanoparticle-
Oligonucleotide Conjugates

10   Five microliters of each probe 1 and 2 (Figure 12A) were combined to a final concentration of 0.1 M NaCl with buffer (10 mM phosphate, pH 7), and 1 microliter of human urine was added to the solution. When this solution was frozen, thawed, and then spotted on a C-18 TLC plate, a blue

15   color did not develop. To a similar solution containing 12.5 microliters of each probe and 2.5 microliters of human urine, 0.25 microliters (10 picomoles) of target 3 (Figure 12A) was added. The solution was frozen, thawed and then spotted onto a C-18 TLC plate, and a blue spot was obtained.

20   Similar experiments were performed in the presence of human saliva. A solution containing 12.5 microliters of each probe 1 and 2 and 0.25 microliters of target 3 was heated to 70°C. After cooling to room temperature, 2.5 microliters of a saliva solution (human saliva diluted 1:10

25   with water) was added. After the resultant solution was frozen, thawed and then spotted onto a C-18 TLC plate, a blue spot was obtained, indicating hybridization of the probes with the target. In control experiments with no target added, blue spots were not observed.

30

Example 10:   Assays Using Nanoparticle-
Oligonucleotide Conjugates

An assay was performed as illustrated in Figure 13A.

5   First, glass microscope slides, purchased from Fisher

scientific, were cut into approximately 5 x 15 mm pieces,

using a diamond tipped scribing pen. Slides were cleaned by

soaking for 20 minutes in a solution of 4:1 $H_2SO_4:H_2O_2$ at

50°C. Slides were then rinsed with copious amounts of

10   water, then ethanol, and dried under a stream of dry

nitrogen. Thiol-modified DNA was adsorbed onto the slides

using a modified procedure reported in the literature

(Chrisey et al., *Nucleic Acids Res.*, **24,** 3031-3039 (1996)

and Chrisey et al., *Nucleic Acids Res.*, **24,** 3040-3047

15   (1996)). First, the slides were soaked in a 1% solution of

trimethoxysilylpropyldiethyltriamine (DETA, purchased from

United Chemical Technologies, Bristol, PA) in 1 mM acetic

acid in Nanopure water for 20 minutes at room temperature.

The slides were rinsed with water, then ethanol. After

20   drying with a dry nitrogen stream, the slides were baked at

120°C for 5 minutes using a temperature-controlled heating

block. The slides were allowed to cool, then were soaked in

a 1 mM succinimidyl 4-(malemidophenyl)-butyrate (SMPB,

purchased from Sigma Chemicals) solution in 80:20

25   methanol:dimethoxysulfoxide for 2 hours at room temperature.

After removal from the SMPB solution and rinsing with

ethanol, amine sites that were not coupled to the SMPB

crosslinker were capped as follows. First, the slides were

soaked for 5 minutes in a 8:1 THF:pyridine solution

30   containing 10% 1-methyl imidazole. Then the slides were

110

soaked in 9:1 THF:acetic anhydride solution for five minutes. These capping solutions were purchased from Glen Research, Sterling, VA. The slides were rinsed with THF, then ethanol, and finally water.

5   DNA was attached to the surfaces by soaking the modified glass slides in a 0.2 OD (1.7 μM) solution containing freshly purified oligonucleotide (3' thiol ATGCTCAACTCT [SEQ ID NO:33]). After 12 hours of soaking time, the slides were removed and rinsed with water.

10   To demonstrate the ability of an analyte DNA strand to bind nanoparticles to the modified substrate, a linking oligonucleotide was prepared. The linking oligonucleotide was 24 bp long (5' TACGAGTTGAGAATCCTGAATGCG [SEQ ID NO:34]) with a sequence containing a 12 bp end that was

15   complementary to the DNA already adsorbed onto the substrate surface. The substrate was then soaked in a hybridization buffer (0.5 M NaCl, 10 mM phosphate buffer pH 7) solution containing the linking oligonucleotide (0.4 OD, 1.7 μM) for 12 hours. After removal and rinsing with similar buffer,

20   the substrate was soaked in a solution containing 13 nm diameter gold nanoparticles which had been modified with an oligonucleotide (TAGGACTTACGC 5' thiol [SEQ ID NO:35]) that is complementary to the unhybridized portion of the linking oligonucleotide attached to the substrate. After 12 hours

25   of soaking, the substrate was removed and rinsed with the hybridization buffer. The glass substrate's color had changed from clear and colorless to a transparent pink color. See Figure 19A.

Additional layers of nanoparticles were added to the
slides by soaking the slides in a solution of the linking
oligonucleotide as described above and then soaking in a
solution containing 13 nm gold nanoparticled having

5   oligonucleotides (3' thiol ATGCTCAACTCT [SEQ ID NO:33])
attached thereto. After soaking for 12 hours, the slides
were removed from the nanoparticle solution and rinsed and
soaked in hybridization buffer as described above. The
color of the slide had become noticeably more red. See

10   Figure 19A. A final nanoparticle layer was added by
repeating the linking oligonucleotide and nanoparticle
soaking procedures using 13 nm gold nanoparticles which had
been modified with an oligonucleotide (TAGGACTTACGC 5' thiol
[SEQ ID NO:35]) as the final nanoparticle layer. Again, the

15   color darkened, and the UV-vis absorbance at 520 nm
increased. See Figure 19A.

To verify that the oligonucleotide modified gold
nanoparticles were attached to the oligonucleotide modified
surface through DNA hybridization interactions with the

20   linking oligonucleotide, a melting curve was performed. For
the melting experiment, a slide was placed in a cuvette
containing 1.5 mL of hybridization buffer, and an apparatus
similar to that used in Example 2, part B, was used. The
absorbance signal due to the nanoparticles (520 nm) was

25   monitored at each degree as the temperature of the substrate
was increased from 20°C to 80°C, with a hold time of 1
minute at each integral degree. The nanoparticle signal
dramatically dropped when the temperature passed 52°C. See
Figure 19B. A first derivative of the signal showed a

melting temperature of 55°C, which corresponds with the temperature seen for the oligonucleotide-nanoparticle conjugates and linking oligonculeotides hybridized in solution. See Figure 19B.

5

Example 11:   Assay of a Polyribonucleotide Using Nanoparticle-Oligonucleotide Conjugates as Probes

10   The previous Examples utilized oligo-deoxyribonucleotides as targets in the assays. The present example demonstrates that the nanoparticle-oligonucleotide conjugates can also be used as probes in assaying a polyribonucleotide. The experiment was carried out by

15   adding 1 μL of a solution of poly(rA) (0.004 A_{260} Units) to 100 μL of of gold nanoparticles (~ 10 nM in particles) conjugated to dT_{20} (a 20-mer oligonucleotide containing thymidylate residues) through a mercaptoalkyl linker at the 5'-terminus. The conugation procedure was that described in

20   Example 3. Following freezing in a Dry Ice/isopropyl alcohol bath, thawing at room temperature, and spotting on a C18 TLC plate as described in Example 4, a blue spot characteristic of aggregation of the nanoparticles by hybridization was observed. Control experiments carried out

25   in absence of the target gave a pink spot, rather than a blue spot.

Example 12:   Assay for Protective Antigen DNA Segment of Anthrax Using Nanoparticle-
30   Oligonucleotide Conjugates

113

In many cases amplification of a double-stranded DNA target by PCR is needed to provided sufficient material for an assay. The present example demonstrates that the nanoparticle-oligonucleotide conjugates can be used to assay

5   for a DNA strand in the presence of its complement (*i.e.*, assaying for a single strand after thermal dehybridization of a double-stranded target) and can recognize and specifically bind to an amplicon obtained from a PCR reaction.

10   A PCR solution containing a 141 base pair duplex amplicon of the Protective Antigen segment of Anthrax was provided by the Navy (sequence given in Figure 23). The assay for this amplicon was carried out by isolating the DNA from 100 μL of the PCR solution using a Qiaquick Nucleotide

15   Removal Kit (Qiagen, Inc., Santa Clarita, CA) and the standard protocol for this kit, with the exception that elution of the DNA was effected with 10 mM phosphate buffer at pH 8.5, rather than with the buffer provided with the kit. The eluant was then evaporated to dryness on a Speed

20   Vac (Savant). To this residue was added 5 μL of a master mix prepared by mixing equal volumes of each of two solutions of two different oligonucleotide-nanoparticle probes (see Figure 23). Each oligonucleotide-nanoparticle probe was prepared as described in Example 3. The solutions

25   of the probes which were combined to form the master mix were prepared by adding 10 μL of 2 M NaCl and 5 μL of oligonucleotide blocker solution (50 pmoles of each Blocker oligonucleotide (see Figure 23 and below) in a 0.3 M NaCl, 10 mM phosphate, pH 7.0., solution) to 5 μL of full-strength

114

(about 10 nM) nanoparticle-oligonucleotide solution. The

amplicon-probe mixture was heated to 100°C for 3 minutes,

then frozen in a DRY ICE/ethanol bath and allowed to come to

room temperature. A small aliquot (2 μL) was spotted on a

5   C18 TLC plate and allowed to dry. A strong blue spot

indicative of hybridization was obtained.

Control tests carried out in the same manner in absence

of the the amplicon target DNA, in the absence of Probe 1,

in the absence of Probe 2, or in the absence of the sodium

10   chloride, were all negative, that is, gave a pink spot.

Similarly a test carried out using probes 1 and 2 with a PCR

amplicon derived from the Lethal Factor segment of Anthrax

in place of the Protective Antigen Segment was negative

(pink spot).   These controls confirmed that both probes

15   were essential, that salt conditions appropriate for

hybridization were needed, and that the test was specific

for the specified target sequence.

The oligonucleotide Blockers were added to inhibit

binding of the second strand of the initial duplex target

20   (*i.e.*, the strand complementary to the target strand) to

regions of the target nucleic acid strand outside the

segment that binds to the probes (see Figure 23 for

sequences), since such binding interferes with binding of

the nanoparticle olignucleotide probes to the target strand.

25   In this example, the Blocker oligonucleotides were

complementary to the single-stranded target in regions not

covered by the probes. An alternative scheme is to use

blocker oligonucleotides that are complementary to the PCR

complementary strand (the strand complementary to the target

115

strand) outside the region that competes with the probe oligonucleotides.

Example 13: Direct assay of PCR Amplicons without
5 isolation of the amplicons from the PCR
solution

The procedure described in Example 12 involved separation of the PCR amplicon from the PCR solution before
10 addition of the nanoparticle-oligonucleotide probes. For many purposes it would be desirable to be able to carry out the assay directly in the PCR solution without preliminary isolation of the polynucleotide products. A protocol for such an assay has been developed and is described below.
15 This protocol has been performed successfully with several PCR products derived under standard conditions using a GeneAmp PCR Reagent Kit with Amplitaq DNA polymerase.

To 50 μL of the PCR sample solution, 5 μL of a mixture of two gold nanoparticle-oligonucleotide probes (0.008 A_{520}
20 Units of each) was added, followed by addition of a solution made up from 1 μL of Blocker oligonucleotides (10 pmoles each), 5 μL of 5 M NaCl, and 2 μL of 150 mM $MgCl_2$. This mixture was heated for 2 minutes at 100°C to separate the strands of the duplex target, the tube was immersed directly
.25 in a cold bath (e.g., Dry Ice/ethanol) for 2 minutes, then removed, and the solution allowed to thaw at room temperature (the freeze-thaw cycle facilitates hybridization of the probes with the target oligonucleotide). Finally, a few μL of the solution were spotted on a plate (e.g., C18 RP
30 TLC plate, a silica plate, a nylon membrane, etc.). As

116

usualy, blue color signifies the presence of the targeted nucleic acid in the PCR solution; a pink color is negative for this target.

5   Example 14:   Direct Recognition of Duplex
                        Oligonucleotides Without
                        Dehybridization, Using Assembly of
                        Nanoparticle-Oligonucleotide Conjugates

10   In the previous Examples, double-stranded targets were dehybridized by heating to generate single strands which interacted with single-stranded oligonucleotide probes bound to nanoparticles. The present example demonstrates that in cases where triple-stranded complexes can form, double-

15 stranded oligonucleotide sequences can be recognized by the nanoparticle probes without prior dehybridization of the target.

Tests were carried out with two different systems-- polyA:polyU and $dA_{40}:dT_{40}$ -- by adding 1 μL of a solution

20 containing 0.8 A_{260} Units of the target duplex in 100 μL of buffer (0.1 M NaCl, 10 mM phosphate, pH 7.0) to 100 μL of a colloidal solution of Au-sdT_{20} nanoparticle-oligonucleotide conjugate (~10 nM in particles; see Example 11) in 0.3 M NaCl, 10 mM phosphate buffer at pH 7.0. Subsequent quick

25 freezing by immersing the tube in a Dry Ice/isopropyl alcohol bath and thawing by removing the tube from the bath and letting it stand at room temperature (22°C), followed by spotting 3 μL of the solution on a C18 TLC plate, afforded a blue spot characteristic of hybridization and aggregation of

30 the nanoparticles.

117

The rationale for this test is that the nanoparticle probes (bearing pyrimidine oligonucleotides in this example) bind in a sequence specific manner at purine oligonucleotide/pyrimidine oligonucleotide sites along the

5   duplex target. Since many binding sites are available on each double stranded entity, the binding leads to formation of an aggregate of nanoparticles. The results show that this assay, based on formation of triple-stranded complexes involving the nanoparticle probes, works both for oligoribo-

10   and oligodeoxyribonucleotide double-stranded targets.

EXAMPLE 15:   Assay Employing Both Fluorescence And

Colorimetric Detection

All hybridization experiments were performed in a 0.3 M

15   NaCl, 10 mM phosphate, pH 7.0, buffer solution.
AcetatePlus™ filtration membranes (0.45 μm) were purchased from Micron Separations Inc., Westboro, MA. Alkylamine-functionalized latex microspheres (3.1 μm) were purchased from Bangs Laboratories, Fishers IN.   Fluorophore-labeled

20   oligonucleotides functionalized with alklylamino groups at the 3'-terminus were synthesized using standard phosphoramidite chemistry (Eckstein, ed., in *Oligonucleotides and Analogues*, 1st ed., Oxford University, New York, N.Y. 1991) with an Amino-Modifier C7 CPG solid

25   support (Glen Research) and a 5'-fluorescein phosphoramidite (6-FAM, Glen Research) on an Expedite 8909 synthesizer and were purified by reverse phase HPLC. They were attached to the amine-functionalized latex microspheres by means of diisothiocyanate coupling to yield a dithiourea linkage as

118

described in Charreyre et al., *Langmuir*, **13**, 3103-3110 (1997). Briefly, a DMF solution of a one thousand fold excess of 1,4-phenylene diisothiocyanate was added to an aqueous borate buffer solution (0.1 M, pH 9.3) of the amino-

5   modified oligonucleotide. After several hours, the excess 1,4-phenylene diisothiocyanate was extracted with butanol and the aqueous solution lyophilized. The activated oligonucleotides were redissolved in borate buffer and reacted with the amino-functionalized latex microspheres in

10   a carbonate buffer (0.1 M, pH 9.3, 1 M NaCl). After 12 hrs, the particles were isolated by centrifugation and washed three times with buffered saline solution (0.3 M NaCl, 10 mM phosphate pH 7.0). The 5'-oligonucleotide-modified gold nanoparticle probes were prepared as described in Example 3.

15   The target oligonucleotide (1-5 µl, 3 nM) was added to 3 µl of fluorophore-labeled oligonucleotide-modified latex microsphere probe solution (3.1 µm; 100 fM). After 5 minutes, 3 µl of the 5' oligonucleotide-modified gold nanoparticle probe solution (13 nm; 8 nM) were added to the

20   solution containing the target and latex microsphere probes. Upon standing for an additional 10 minutes, the solution containing both probes and target was vaccuum-filtered through the AcetatePlus membrane. The membrane retained the relatively large latex particles and allowed any non-

25   hybridized gold nanoparticle probes to pass through. In the presence of a sufficient concentration of target, the latex microspheres and the gold nanoparticles hybridized with the target, and a red spot was observed on the membrane (positive result). A control experiment was always carried

out where the aliquot of solution containing the target oligonucleotide was replaced by an equal volume of water. In this case, a white spot was left on the membrane (negative result). For a 24-base-pair model system, using

5   the unaided eye, 3 femtomoles of target oligonucleotide could be detected colorimetrically.

A double-stranded target oligonucleotide (1-5 μl, 20 nM), 3 μl of a solution of fluorophore-labeled-oligonucleotide-latex microspheres (3.1 μm; 100 fM) and 3 μl

10   of a solution of 5'-oligonucleotide-gold nanoparticles (13 nm; 8 nM) were combined and heated to 100 °C for 3 minutes. Then, the solution was immediately frozen by immersing the reaction vessel containing it in a liquid N_2 bath for 3 minutes. This solution was then thawed at room temperature

15   and filtered as described above. For a 24-base pair model system, using the unaided eye, 20 femtomoles of duplex target oligonucleotide could be detected colorimetrically.

When monitored by fluorescence, the detection method described above proved to be difficult due to background

20   fluorescence from the membrane. This problem was overcome by "washing" the latex microspheres by centrifugation to remove excess gold nanoparticle probes before spotting an aliquot on a reverse-phase TLC plate. The hybridization experiments were performed as described above. After

25   hybridization was effected between the probes and target, 10 μl of buffer were added to the solution, which was subsequently centrifuged at 10,000 x g for 2 minutes. The supernatant was removed, and 5 μl of buffer were added to help resuspend the precipitate. A 3 μl aliquot was then

120

spotted on a reverse-phase TLC plate. For both single-
stranded and duplex target oligonucleotides, 25 femtomoles
could be detected colorimetrically by the naked eye.
Fluorescent spots could be visualized by the naked eye with
5   a hand-held UV-lamp until the target amount in the 3 μl
aliquot used to form the spot was as low as 50 femtomoles.
It is believed that optimization of this system will allow
for detection of even lower amounts of target nucleic acid.